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Infection with high-risk human papillomaviruses (HPVs) is the main cause of cervical 
cancer, the second most common cause of cancer-related mortality in women worldwide. High-
risk HPV types, such as HPV-16, express two oncoproteins, E6 and E7, which function to 
subvert critical host cell cycle control mechanisms in order to promote viral genome 
amplification. Disruption of the pRB signaling axis and the p53-mediated stress response by the 
HPV E7 and E6 oncoproteins, respectively, results not only in aberrant proliferation but also in 
host cellular changes that can promote genomic instability. The high-risk HPV-16 E7 
oncoprotein was found to induce centrosome abnormalities thereby disrupting mitotic fidelity 
and increasing the risk for chromosome missegregation and aneuploidy. Aneuploidy is 
frequently found in pre-malignant high-risk HPV-associated lesions and is a critical factor for 
malignant progression. This thesis was designed to determine the molecular mechanisms behind 
the ability of HPV-16 E7 to rapidly induce centriole overduplication. This rapid induction was 
found to be possible through the simultaneous formation of more than one daughter centriole at 
single maternal centrioles (centriole multiplication). It was previously discovered that the 
centriole multiplication pathway relied on cyclin E, CDK2 and PLK4. However, it was not 
known before how these molecular players cooperate in the centriole multiplication pathway or 
how HPV-16 E7 expression promotes the activation of this pathway. Here, we report that cyclin 
E/CDK2 mediates the aberrant recruitment of PLK4 to maternal centrioles. This initial 
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recruitment step was not sufficient to induce centriole multiplication unless PLK4 protein levels 
were increased. We found that PLK4 protein levels were controlled by proteolysis, specifically 
by CUL1-based E3 ubiquitin ligase complexes localized at maternal centrioles. SCF activity was 
found to control not only baseline PLK4 protein stability but its activity-dependent degradation 
following cyclin E/CDK2 overexpression. High-risk HPV-16 E7 is known to deregulate cyclin 
E/CDK2 complexes and we found that ectopic expression of HPV-16 E7 promoted the aberrant 
recruitment of PLK4 to maternal centrioles. Since our previous experiments have shown that 
aberrant recruitment of PLK4 is not sufficient to drive centriole overduplication, we determined 
whether HPV-16 E7 may also disrupt PLK4 expression. We found that HPV-16 E7, but not low-
risk HPV proteins or mutants of HPV-16 E7 that lack the ability to induce centriole 
overduplication, causes a moderate but significant upregulation of PLK4 mRNA. Besides 
centriole duplication control, we discovered that proteolysis also regulates other aspects of 
centriole synthesis such as regulation of daughter centriole length. Defining the precise 
molecular circuitry of centriole biogenesis will aid not only in deepening the current 
understanding of centriole biogenesis but also aid in identification of novel targets, such as 
CDK2 or  PLK4, for small molecules to prevent centriole abnormalities, mitotic infidelity and 
malignant progression in pre-invasive high-risk HPV-associated lesions. 
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THESIS OUTLINE  
Chapter 1 consists of a general introduction to human papillomaviruses and their association 
with cancer. The role of the high-risk HPV oncoproteins in the viral life cycle and in 
deregulating centrosome duplication control leading to genomic instability will be discussed. 
This chapter also provides a review of the centrosome duplication cycle and presents evidence 
suggesting that HPV-16 E7 oncoprotein disruption of this cycle is a key factor in promoting 
HPV-associated tumorigenesis.    
 
Chapter 2 describes the Skp1-CUL1-F-box (SCF)-mediated control of centriole biogenesis. 
CUL1 was shown to localize to centrioles in a cell cycle dependent manner. Knock-down of 
CUL1 led to centriole overduplication in the form of centriole multiplication.  Intriguingly, this 
centriole multiplication phenotype mimicked that induced by high-risk HPV-16 E7 protein 
expression. Further experiments revealed that CUL1-mediated restraint of centriole biogenesis 
involved the degradation of polo-like kinase 4 (PLK4) at maternal centrioles. Additionally, it 
was shown that CUL1 is critical for the degradation of active PLK4 following deregulation of 
cyclin E/CDK2 activity as well as baseline PLK4 protein stability. Finally, we discovered that 
ectopic expression of CAND1, an inhibitor of SCF-ligase complexes, promoted centriole 
multiplication and stabilized PLK4 protein levels. These results suggest that active CUL1 may 
 xi 
function as a tumor suppressor by regulating PLK4 protein levels and thereby restraining 
excessive daughter centriole formation at maternal centrioles. 
 
Chapter 3 describes the mechanism by which HPV-16 E7 induces centriole multiplication. We 
detected aberrant PLK4 protein expression at maternal centrioles in primary human keratinocytes 
engineered to stably express HPV-16 E7. Real-time quantitative reverse transcriptase (qRT-
PCR) revealed an increase in PLK4 transcription in keratinocytes stably expressing HPV-16 E7. 
The ability of HPV-16 E7 to upregulate PLK4 mRNA was found to be dependent on its ability to 
degrade the retinoblastoma (pRb) protein and interact with histone deacetylases (HDACs), 
suggesting a role of E2F-mediated gene transcription in deregulation of PLK4. Collectively, 
these results highlight the critical role of PLK4 as a regulator of centriole biogenesis and identify 
PLK4 as a novel target for small molecules to prevent centriole abnormalities, mitotic infidelity 
and malignant progression in pre-invasive HPV-associated neoplasms. 
 
Chapter 4 describes the role of proteolysis in maintaining daughter centriole length. Here, we 
show that inhibition of the proteasome by Z-L3VS or MG132 induces abnormal elongation of 
daughter centriole microtubules to approximately four times their normal length. Using an 
siRNA screen, we identified a total of nine gene products that either attenuated (seven) or 
promoted (two) abnormal Z-L3VS-induced daughter centriole elongation. Our hits included 
known regulators of centriole length including CPAP and CP110 but, interestingly, a number of 
proteins involved in microtubule stability and anchoring as well as centrosome cohesion. These 
results underscore that daughter centriole length is not limited by structural constraints but is 
regulated by proteolysis. They furthermore highlight the complexity of daughter centriole length 
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control and provide a framework for future studies to dissect the molecular details of this 
process. 
 
Chapter 5 summarizes findings from each of the previous sections and develops a 
comprehensive model of how the HPV-16 E7 oncoprotein disrupts multiple pathways controlling 
centriole biogenesis inducing centriole multiplication. This chapter will highlight results which 
illustrate the importance of proteolysis in controlling centriole duplication processes. Future 
directions will also be discussed. 
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1.0  GENERAL INTRODUCTION 
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1.1 HUMAN PAPILLOMAVIRUSES (HPVS) AND CANCER 
Infection with high-risk human papillomaviruses (HPVs) is the main cause of cervical 
cancer, which is the second most common cause of cancer related mortality in women worldwide 
[1]. Studies have shown that high-risk HPV DNA is present in >90% of cervical cancers [2]. 
There are over 100 HPV genotypes, which are classified into two major groups: cutaneous and 
mucosal. Infection with cutaneous HPV types, for example HPV-1 and -2, usually leads to 
benign diseases such as skin and plantar warts. However, some cutaneous HPV types, such as 
HPV-5 and HPV-8, have been associated with skin carcinoma in immunodeficient patients and 
in patients with the skin disease epidermodysplasia verruciformis (EV) [3, 4]. Mucosal HPVs are 
further subdivided into low-risk and high-risk HPVs [5]. Low-risk types such as HPV-6 and -11 
are associated with benign lesions such as condylomata acuminata and oral and laryngeal 
papillomas [1]. High-risk HPV types such as HPV-16, -18, -31, -33, and -45 are associated with 
anogenital and a subset of oropharyngeal tract cancers, in particular cervical carcinoma. 
Epidemiological and biological studies have shown that HPV-16, and -18 are the most oncogenic 
types within the high-risk group accounting for 50% and 20%, respectively, of cervical cancers 
[2].  
Despite the high prevalence of HPV infection in sexually active women, most HPV 
infections are self-limiting and transient. Progression to cancer is a result of both persistent 
infection with high-risk HPV as well as additional co-factors such as tobacco use, exogenous 
estrogen and UV-exposure [6]. Mounting evidence suggests that genomic instability may also be 
an important co-factor in promoting malignant progression. This is supported by evidence 
suggesting that patients with Fanconia Anemia (FA), a rare X-linked and autosomal recessive 
chromosomal instability syndrome, are at a significantly higher risk for developing HPV-
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associated cancerous lesions [7-9]. In addition, genomic instability is a frequent and early event 
during HPV-associated malignant progression and detected in a significant fraction of pre-
invasive high-risk HPV-associated lesions [10, 11]. Importantly, there is evidence suggesting 
that HPV oncoproteins can by themselves drive genomic instability [12, 13]. Together, these 
observations lend support to the idea that genomic instability is a critical factor for malignant 
progression of high-risk HPV-associated cancers.  
  Recently, prophylactic vaccines have been developed against HPV-6, -11, -16, and -18 
and a small but growing proportion of the world-wide population is being vaccinated to prevent 
HPV infection [14]. However, the vaccines are currently still expensive and prevention of HPV-
associated carcinoma is only effective in people with no prior exposure to high-risk HPV. 
Understanding the exact mechanisms by which high-risk HPV oncoproteins promote 
chromosomal instability will not only provide novel insights into basic biological processes but 
may also contribute to the development of better preventive and therapeutic options 
complimentary to preventative vaccination.  
1.2 GENERAL BIOLOGY OF HPVS 
High-risk HPVs, such as HPV-16, are circular double-stranded DNA viruses of 
approximately 8,000 base pairs. Oncogenic HPV genomes contain eight open reading frames 
(ORFs) which are expressed as polycistronic mRNAs in a temporal manner under control of the 
non-coding long control region (LCR) (Fig. 1). The LCR contains the viral origin of DNA 
replication and important transcriptional control elements recognized by both cellular and virally  
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Figure 1. The HPV-16 Genome. 
HPV-16 contains eight open reading frames (ORFs) under the transcriptional control of the non-coding long control 
region (LCR). HPV early (E) genes control the viral lifecycle and late (L) genes encode viral structural proteins. 
HPV-16 contains two major promoters an early promoter (P97) and a late promoter (P670). The early promoter is 
upstream of the E6 ORF and is active early following infection, while the late promoter is found within the E7 ORF 
and is activated upon differentiation during the productive phase of the viral lifecycle  
 
encoded regulatory proteins [15]. HPV (E) early transcripts control viral gene transcription and 
deregulate host targets to allow amplification of the viral genome in terminally growth-arrested  
cells. Early transcripts of high-risk HPV-16 are under control of a single promoter P97, contained  
within the LCR [15]. HPV late (L) transcripts, L1 and L2, encode for the major and minor viral 
capsid proteins, respectively. Late transcripts of high-risk HPV-16 are under control of the late 
promoter P670, residing within the E7 coding region, which only becomes active in terminally 
differentiating keratinocytes [16]. 
The HPV lifecycle is intimately linked to the differentiation state of host keratinocyte 
cells [15]. HPVs are thought to infect cells of the basal layer of the epithelium through 
microabrasions to the epithelium surface. The basal strata contain stems cells and transit-
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amplifying cells which undergo cell division in order to maintain the suprabasal layer [15]. As 
progeny cells of the basal epithelium layer migrate towards the upper stratum they normally 
undergo terminal differentiation and permanently exit the cell cycle. HPV infected cells remain 
capable of cell cycle progression through the actions of the HPV oncoproteins [15].  
Upon HPV infection, E1 and E2 gene expression is activated. The E1 protein functions as 
a DNA helicase and interacts with the E2 protein to bind to the viral origin of replication [17-19]. 
E2 also acts as a transcriptional regulator both activating and limiting the expression of the viral 
genes E6 and E7 during the early phase of virus infection. The virus does not encode any of its 
own replicative enzymes and is entirely dependent on host cell DNA replication machinery. As 
viral replication occurs in differentiating keratinocytes that have permanently withdrawn from 
the cell division cycle, the E6 and E7 oncoproteins have evolved to ensure the formation of an S-
phase milieu which is necessary for replication of the viral genome [20].  
The E4 and E5 proteins play a less well understood role in the viral lifecycle. The E4 
protein may play a role in virus egress from the cell by inducing the collapse of the cytokeratin 
network [21]. The E5 protein is necessary for optimal growth of the virus, possibly involving 
interaction with the epidermal growth factor receptor (EGFR) [22, 23].  
During the productive phase of the viral lifecycle, the HPV genomes replicate on average 
once per cell cycle during S-phase, in synchrony with host cell DNA replication [15]. The HPV 
genome is normally maintained episomally, at approximately 50-100 copies per cell [24]. Once 
an infected cell reaches the upper epidermal layers and undergoes terminal differentiation, a 
burst of viral DNA replication occurs, producing the viral genomes to be packaged into progeny 
virions [15]. 
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1.3 HIGH RISK HPV ONCOPROTEINS 
High-risk HPVs express two oncoproteins, E6 and E7, which function to de-regulate the 
host cell cycle in order to promote amplification of the viral genome. Long-term expression of 
HPV E6 and E7 oncoproteins are known to both extend the life-span of primary human cells and 
facilitate their immortalization [25]. High-risk HPV E6 and E7 gene expression is consistently 
up-regulated in HPV-associated malignant tumors, in which viral genomes are frequently found 
integrated into host cell chromosomes [26].  
 Integration of the viral genome terminates the productive lifecycle of the virus. Viral 
genome integration can occur throughout the host genome, but most frequently is found at 
common fragile sites [27]. Integration most commonly results in deletion of a large segment of 
the viral genome, while the E6 and E7 ORFs remain intact along with the LCR, which lies 
upstream of the integration site within the viral genome [26]. The E1 and E2 viral genes are 
disrupted, resulting in higher levels of both E6 and E7 gene transcription.  
However, overexpresion of the HPV-16 E6 and E7 genes is not necessary for induction 
of genomic instability, suggesting that the high-risk HPV E6 and E7 oncoproteins promote an 
increased risk of malignant progression even when their expression is tightly controlled [28].  
1.3.1 The HPV-16 E7 oncoprotein 
High-risk HPV E7 proteins are small phosphoproteins with no known human homologs 
[29]. HPV E7 oncoproteins contain two conserved domains (CR1 and CR2) which share 
sequence similarity to both adenovirus E1A and SV40 large T antigen (Fig. 2) [30, 31]. High-
risk HPV E7 inactivates the retinoblastoma tumor suppressor protein (pRB), and the related
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Figure 2. Schematic of the HPV-16 E7 oncoprotein. 
The HPV-16 E7 oncoprotein is a small 98 amino acid protein containing two conserved domains, CR1 and CR2, and 
a carboxy-terminal region characterized by two metal-binding regions. The CR2 domain contains the LXCXE pRB-
binding domain and a caesin kinase II phosphorylation motif. The HPV-16 E7 mutant with deletion of amino acids 
21-24 (Δ21-24) is unable to bind and degrade pRB. The HPV-16 E7 mutant with amino acid substitution at L67 
(L67R) is unable to interact with HDACs and has a decreased ability to transactivate gene transcription.     
 
pocket protein family members p107 and p130, which are responsible for regulating E2F-
mediated transcription of S-phase genes [32-34]. Specifically, HPV-16 E7 binds to and induces 
the proteasomal degradation of pRB by cullin 2-containing E3 ubiquitin ligases [34-36]. High-
risk HPV E7 associates with pRB and its family members through a Leu-X-Cys-X-Glu 
(LXCXE) motif located within the CR2 homology domain [37]. Additional sequences located in 
the amino-terminal CR1 homology domain are necessary for pRB degradation [35]. High-risk 
HPV-16 E7 has also been shown to inactivate p600, a pRB-associated protein [38, 39].  
An important functional difference between low-risk and high-risk HPV E7 oncoproteins 
lies in their ability to bind and degrade pRB, p107 and p130. High-risk HPV-16 E7 binds with a 
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higher affinity to pRB-family members than do low-risk HPV-6 E7 proteins. In the case of pRB, 
this difference maps to a single amino acid change within the pRB-binding domain which 
confers high-affinity binding [40]. Low-risk HPV-6 also binds p107 and p130 with a lower 
affinity however this difference does not map to the same residue as pRB-binding efficiency 
[41]. Moreover, HPV-6 E7 has recently been shown to destabilize p130, but not pRB or p107, 
suggesting that disruption of signaling pathways controlled by p130 are necessary for the 
productive stage of the viral lifecycle and that pRB and/or p107 degradation are important for 
carcinogenesis [41].  
To further disrupt host gene expression control, HPV-16 and HPV-31 E7 oncoproteins 
also interact with histone deacetylases type -1 and -2 (HDAC-1, and -2) [42, 43]. HDACs 
function as transcriptional repressors by reversing acetyl modifications of lysine residues on 
histones. The indirect association between oncogenic HPV-16 E7 and HDACs is mediated by 
Mi2β, a component of the NURD histone deacetylase complex [42]. This interaction is 
dependent on the integrity of two Cys-X-X-Cys motifs in the HPV E7 oncoprotein carboxy-
terminus and results in increased E2F-mediated gene transcription from HDAC responsive 
promoters [42]. High-risk HPV-16 E7 also associates with histone acetyl transferases (HATs) 
such as, p300 and pCAF, which function to activate transcription and stimulate cellular 
proliferation [44, 45].  
In addition to chromatin remodeling, high-risk HPV-16 E7 can directly alter cellular 
transcription through interaction with E2F1. This interaction results in the pRB-independent 
enhancement of E2F-mediated gene transcription [46]. However, the promoter of E2F6, a 
transcriptional repressor responsible for directing cell cycle exit, is also E2F-responsive [47]. 
The HPV-16 E7 oncoprotein has therefore evolved to directly associate with E2F6 resulting in 
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inactivation of its transcriptional repression and maintenance of an S-phase like environment 
[48].  
Together, along with the ability of HPV-16 E7 to interact with cyclin/CDK complexes 
and its ability to overcome cellular growth arrest signals mediated by the cyclin dependent kinase 
(CDK) inhibitors p21Cip1 and p27Kip1, the HPV E7 oncoprotein profoundly disrupts the pRB-
signaling axis to favor replication of the viral genome [49-51]. Why high-risk HPV E7 has 
evolved to target a multitude of G1/S checkpoint components to achieve this goal is currently 
unknown. 
1.3.2 The HPV-16 E6 oncoprotein 
Disruption of the host cell cycle by HPV-16 E7 is likely to activate cellular stress 
responses and apoptotic signaling cascades. The HPV E6 oncoprotein has evolved to inhibit the 
host cell response to unscheduled cell cycle entry by mediating the degradation of p53. High-risk 
E6 degrades p53 by re-directing a host cell HECT domain containing E3 ubiquitin ligase, E6-
associated protein (E6AP) [52]. Moreover, HPV-16 E6 binds the transcriptional co-activators 
CBP/p300 and decreases the ability to activate p53-responsive promoter elements [53]. High-risk 
HPV E6 has been suggested to switch p53-p300 from an activating to a repressor complex 
independently of E6AP [54]. 
High-risk HPV E6 has additional p53-independent functions that are important for 
cellular transformation and immortalization. Oncogenic HPV E6 contains a PDZ-domain binding 
motif, X-(S/T)-X-(V/I/L)-COOH, that is unique to high-risk HPV E6 and is not present in low-
risk HPV E6 [55]. The HPV E6 oncoprotein binds PDZ-containing host proteins targeting them 
for degradation in both an E6AP-dependent and -independent manner [56-58]. Candidate PDZ-
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containing protein targets include hDlg, hScrib, MAG1-3, and MUPP1 [56, 57].  PDZ-containing 
proteins localize to membrane-cytoskeleton interfaces and have been implicated as molecular 
signaling scaffolds modulating cell growth, polarity and adhesion in response to cell contact. The 
targeted inactivation of these proteins by oncogenic HPV E6 may disrupt cell junctions, induce 
loss of cell polarity and promote cellular transformation [59].   
The oncogenic HPV-16 E6 protein promotes cellular immortalization through the 
transcriptional up-regulation of hTERT, the catalytic subunit of human telomerase, and can 
contribute to telomere maintenance [60]. High-risk HPV E6 can enhance hTERT transcription 
through several mechanisms including association with the transcriptional activator c-Myc 
and/or the E6AP-dependent degradation of a putative transcriptional repressor of the hTERT 
promoter, NFX1-91 as well as others [61, 62].  
1.4 HIGH RISK HPV ONCOPROTEINS AND GENOMIC INSTABILITY 
Genomic instability is a defining phenotype of many malignant tumors including HPV-
associated malignancies [63, 64]. Over 100 years ago, Theodor Boveri hypothesized that 
genomic instability and cancer can result from the presence of extra centrosomes and the 
subsequent formation of multipolar mitoses. Such a disruption of spindle polarity may 
consequently promote chromosome missegregation and ultimately aneuploidy [65]. The major 
consequences of supernumerary centrosomes are polarity disturbances, such as multipolar 
mitoses, and/or merotelic kinetochore attachments, which can lead to lagging chromosomes 
during cell division [66]. However, extra centrosomes do not necessarily lead to cell division 
errors since centrosomes can cluster thereby preserving bipolarity of the mitotic spindle [67]. 
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Nonetheless, centrosome abnormalities have been detected in a wide range of malignant tumors 
including breast, prostate, colon and cervical cancer, and compelling evidence suggests that 
centrosome abnormalities can drive progressive loss of genomic stability and malignant 
progression [63, 68].  
Studies in HPV-associated primary anal human tumors have demonstrated that 
centrosome overduplication correlates with the frequency of cell division errors, which lends 
important support to the notion that the presence of overduplicated centrosomes can promote 
these defects in HPV-associated carcinomas [69].  In line with this finding, the frequency of 
aneuploidy increases with both malignant grade and tumor aggressiveness in HPV-associated 
lesions [70, 71]. Correlating with the increase in aneuploidy, multipolar, specifically tri-polar, 
mitoses are a hallmark of high-risk HPV-associated carcinomas [72].  
In the context of high-risk HPV, centrosome amplification is observed in cells expressing 
episomal HPV-16 genomes, which underscores that viral integration and overexpression of HPV 
E6 and HPV E7 oncoproteins is not required for the disruption of centrosome duplication control 
[28]. HPV-16 E7 expression directly disrupts centriole duplication control resulting in the rapid 
induction of centriole overduplication, whereas HPV-16 E6 expression promotes the 
accumulation of centrioles in cells that are already genomically unstable [72]. Determining the 
pathways that are activated by HPV oncoprotein expression leading to centrosome 
overduplication, cell division errors and ultimately aneuploidy will be important in 
understanding and preventing the earliest steps in malignant progression.    
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1.5 THE CENTROSOME 
The centrosome is the major microtubule-organizing center of most mammalian cells and 
orchestrates bipolar spindle pole formation during mitosis [73]. The centrosome consists of two 
centrioles embedded in a cloud of pericentriolar proteins, also known as pericentriolar material 
(PCM) [74]. The two centrioles differ in age and composition, consisting of an older maternal 
centriole characterized by distal and sub-distal appendage proteins which function to anchor and 
nucleate microtubules, and a younger daughter centriole which does not yet associate with the 
appendage proteins [73]. In order to generate two spindle poles, the single centrosome of a non-
dividing cell must duplicate precisely once, and only once, prior to mitoses in order to ensure 
faithful cell division. 
1.5.1 Centrosome duplication  
Centrosome duplication begins during late mitosis/early G1-phase of the cell division 
cycle, when the two pre-existing centrioles of the single centrosome disengage through the action 
of polo kinase 1 (PLK1) and separase, and move into a near parallel position (Fig. 3) [75]. This 
step is followed by recruitment of polo-like kinase 4 (PLK4) to the wall of the maternal centriole 
at the site of daughter centriole synthesis [76]. Subsequently, structural proteins are recruited to 
the nascent pro-centriole to stabilize and elongate the new daughter centriole. Centrosome 
duplication is complete during late G2-phase of the cell cycle, when the two fully formed 
centriole pairs separate to form the mitotic spindle poles [73]. 
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Figure 3. The centrosome duplication cycle.  
Centrosome duplication occurs in synchrony with the cell division cycle beginning with separation of the two 
centrioles through the actions of PLK1 and separase. This step is followed by recruitment of PLK4, to the wall of 
the pre-existing, or maternal centrioles, at the site of daughter centriole synthesis. Each maternal centriole serves as 
a platform for the synthesis of exactly one daughter centriole. Centriolar structural proteins such as hSAS-6, CPAP, 
alpha-tubulin and others are recruited to stabilize and elongate the daughter centriole. Centrosome duplication is 
complete during the late-G2 phase of the cell cycle, when the two fully formed centriole pairs separate to form the 
mitotic spindle poles.   
1.5.2 Mechanisms of centriole amplification 
There are two mechanisms by which centriole amplification in tumor cells may occur: 
centriole overduplication and centriole accumulation (Figure 4). These two phenotypes can be 
distinguished by immunostaining for markers of older, mature centrioles [77]. Genuine centriole 
overduplication is characterized by the presence of one or two mature maternal centrioles and 
multiple immature daughter centrioles. In contrast, centriole accumulation is defined by the 
presence of multiple maternal centrioles with a normal ratio of daughter centrioles (Fig. 4) [77].  
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Figure 4.  Schematic of centriole amplification phenotypes. 
 (A) Following normal centriole duplication one or two maternal centrioles associate with a single daughter 
centriole to form two functional centrosomes (B) Centriole accumulation occurs due to cytokinesis or other cell 
division errors and results in cells containing more than two maternal centrioles, each associated with a single 
daughter centriole. (C) Centriole overduplication arises due to direct disruption of the centriole duplication cycle and 
is characterized by one or two maternal centrioles in the presence of multiple daughter centrioles. (D) Fluorescence 
microscopic analysis of normal duplicated centrioles and ‘centriole flower’ phenotype induced by PLK4 
overexpression in U-2 OS/centrin-GFP cells.  
 
The distinction between centriole overduplication and accumulation is important because 
cells exhibiting centriole accumulation may arise due to abortive mitoses or cytokinesis errors 
and such cells may not be able to produce viable progeny. Conversely, cells which exhibit a 
genuine centriole overduplication defect are, in general, less genomically altered and hence are 
more likely to give rise to genomically unstable daughter cells. 
In vitro studies have demonstrated that the HPV-16 E7 oncoprotein, in particular, disrupts 
genomic integrity by directly interfering with centriole duplication control. High-risk HPV-16 E7 
 15 
expression produces abnormal centriole numbers in otherwise normal cells prior to the onset of 
genomic instability [78]. In contrast, high-risk HPV-16 E6 expressing cells exhibit centrosome 
accumulation in cells which are already genomically unstable, often expressing markers of 
cellular senescence, and are unlikely to remain in the proliferative pool (see section 1.7) [78].  
1.6 IN VIVO MODELS OF HPV ONCOPROTEIN INDUCED CENTROSOME 
ABNORMALITIES AND MALIGNANT PROGRESSION 
The in vivo role of HPV-16 E7-induced centrosome abnormalities in malignant 
progression is highlighted in a transgenic mouse model of cervical carcinogenesis. Transgenic 
mice expressing HPV-16 E7 driven by a cytokeratin 14 promoter and treated with low doses of 
estrogen develop numerical centrosome abnormalities in the cervical mucosa which progress to 
invasive carcinomas [79]. In contrast, HPV-16 E6 expressing transgenic mice display a 
comparable level of numerical centrosome aberrations but develop only low grade cervical 
lesions that do not progress to malignant tumors [79]. These results suggest that centrosome 
aberrations in the context of HPV-16 E7 expression are associated with a greater risk of 
malignant progression than in HPV-16 E6 expressing cells. Importantly, this underscores that 
centrosome abnormalities that arise in the context of high-risk HPV-16 E6 expression may not 
necessarily contribute to carcinogenesis.  
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1.7 HPV-16 E7 ONCOPROTEIN AND DISRUPTION OF CENTROSOME 
DUPLICATION CONTROL 
Following high-risk HPV-16 E7 expression, supernumerary centrioles appear rapidly and 
within a single cell division cycle, suggesting they arise due to direct disruption of centriole 
duplication control [80]. This was initially difficult to reconcile with the prevailing model of 
centriole duplication described above, where a single maternal centriole initiates the synthesis of 
only a single daughter centriole. Further analysis of HPV-16 E7 induced centriole abnormalities 
led to the discovery that the HPV E7 oncoprotein rapidly induces centriole overduplication 
through stimulation of a novel centriole duplication pathway, referred to as centriole 
multiplication [80]. This pathway is characterized by a single maternal centriole initiating the 
simultaneous synthesis of two or more daughter centrioles (Fig. 4C). Centriole multiplication had 
not previously been observed in the context of an oncogenic stimulus relevant for a major human 
cancer [80]. 
1.7.1 Additional mechanisms of HPV-16 E7-induced centrosome abnormalities 
An HPV-16 E7 mutant with deletion of the amino acid region 21-24 which contains the 
LCXCE motif (HPV-16 E7 Δ21-24, see Figure 2) was found to be unable to induce centriole 
overduplication in both normal and pRB-family deficient mouse embryo fibroblasts [81]. In 
contrast, full-length wild-type HPV-16 E7 was able to induce centriole abnormalities even in 
pRB/p107/p130-deficient cells [81]. These results suggest that the oncogenic HPV E7 protein 
induces centriole overduplication in both pRB-dependent and -independent mechanisms. One 
possible mechanism for pRB-independent induction of supernumerary centrioles is through the 
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ability of HPV-16 E7 to interact with γ-tubulin, a component of the PCM important for 
microtubule nucleation. This interaction, which is pRB-independent, relies on an intact LXCXE 
motif [82]. It has been suggested that disruption of γ-tubulin plays a role in the regulation of 
centrosome duplication and this mechanism may hence contribute to overduplication induced by 
HPV-16 E7 [74].  
Other viral oncoproteins, such as Adenovirus E1A and the HTLV-1 Tax protein have also 
been found to promote centriole overduplication and genomic instability although the underlying 
molecular mechanism appears not to be uniform [83, 84]. 
1.8 THE CENTRIOLE MULTIPLICATION PATHWAY 
Multi-ciliated epithelial cells such as those in the trachea and oviduct can rapidly produce 
hundreds of centrioles during ciliogenesis through the centriole multiplication pathway [85, 86]. 
Besides expression of the high-risk HPV-16 E7 protein, aberrant induction of the centriole 
multiplication pathway can be stimulated in other cell types by overexpression of the centriolar 
structural component hSAS-6 or the protein kinase PLK4 [76, 87, 88]. Despite identification of 
these molecular players it is currently unknown if the HPV-16 E7 oncoprotein induces centriole 
multiplication through deregulation of these proteins or through unidentified regulators of this 
pathway.  
Additional insights that may help to determine how the HPV-16 E7 oncoprotein promotes 
centriole multiplication were recently gained through studies utilizing the proteasome inhibitor 
Z-L3VS [80]. When U-2 OS cells were treated with Z-L3VS centriole multiplication was strongly 
induced with the formation of so-called ‘centriole flowers’ (Figure 4D). Centriole flowers are 
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maternal centrioles which associate with the maximum number of possible daughter centrioles 
[76, 80]. This phenotype was dependent on CDK2, cyclin E and PLK4 [80]. These findings led 
to the hypothesis that centriole biogenesis is normally restrained by proteolysis.  Collectively, 
these findings suggest that the high-risk HPV-16 E7 protein may interfere with either the 
regulation or activity of CDK2, cyclin E and PLK4 and/or the proteolytic control of this pathway 
in order to induce centriole multiplication.    
1.9 CELLULAR PROTEOLYSIS AND THE PROTEOLYTIC CONROL OF 
CENTRIOLE BIOGENESIS 
A substrate is targeted for degradation by the proteasome through addition of a 
polyubiquitin chain to the substrate. This reaction is catalyzed by a three-step enzymatic cascade 
involving a ubiquitin-activating enzyme (E1), a ubiquitin targeting enzyme (E2), and a ubiquitin-
ligase protein (E3). The ubiquitin E3 ligase confers substrate specificity to the reaction [89]. 
Cullin-RING ubiquitin-ligases (CRLs) are members of the largest family of eukaryotic E3 
ligases [90]. Because CRLs are active during late G1 until early mitosis during the onset of 
centriole duplication, proteasome inhibition strongly induces centriole multiplication, and several 
components of CRLs have been localized to the centrosome, CRL activity may be important in 
restraining centriole biogenesis [91-93].  
The CRLs are multisubunit E3 ubiquitin ligase complexes characterized by a common 
cullin-containing scaffold. Human cells express seven cullin subunits (CUL1, -2, -3, -4A, -4B, -
5, and -7) responsible for nucleating the assembly of unique ubiquitin ligase complexes [90]. All 
CRLs consist of a cullin-backbone, a zinc-binding RING-domain containing protein which 
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recruits the ubiquitin-conjugating E2 enzyme, and an adaptor protein which recruits 
interchangeable substrate recognition subunits. In the case of the prototypical CRL, the SKP1-
CUL1-F-box (SCF) ubiquitin ligase complex, SKP1 acts as the adaptor protein interacting with 
substrate recognition subunits containing an F-box domain and a second protein-protein 
interaction domain which recognizes the specific target protein (Fig. 5) [90]. Other CRLs contain 
unique adaptor proteins which recognize substrate recognition subunits with different functional 
motifs [90]. 
CRL activation is a complex process involving several regulatory pathways and 
conjugation of a ubiquitin-like protein to the cullin core component [94]. Addition of Nedd8 
(neddylation) to a carboxy-terminal lysine residue conserved in all cullin subunits enhances the 
activation of the ubiquitin-ligase complex [95]. Removal of Nedd8 (deneddylation) is 
accomplished by the COP9 signalosome in response to depletion of the target substrate [96]. A 
further regulatory protein, CAND1, binds unneddylated cullin-backbones to prevent the 
inappropriate formation and activation of CRL complexes [97].         
In line with the hypothesis that CRL complexes may restrain centriole biogenesis, studies 
performed in Drosophila melanogaster cells demonstrated that PLK4 protein levels were 
controlled by an SCF ubiquitin ligase complex containing the F-box protein Slimb [98, 99]. 
Knock-down of Slimb resulted in PLK4 accumulation and centriole multiplication. The 
mechanism of SCF ligase-mediated regulation of centriole biogenesis in particular the role of β-
TRCP, the mammalian homolog of Slimb, in human cells has not been studied in detail. 
?           The first part of this study reports that SCF E3 ligase activity restrains centriole biogenesis 
through regulation of PLK4 protein level in human cells. We also identify a mechanism for PLK4 
recruitment to maternal centrioles involving the activity of cyclin E/CDK2 complexes and demon- 
strate that PLK4 protein level is the rate-limiting step in the centriole multiplication pathway. 
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Figure 5. Schematic of Skp1-CUL1-F-box (SCF) ubiquitin ligase complexes. 
The SCF ligase, prototypical member of the cullin-RING E3 ubiquitin ligase family, consists of a CUL1-backbone 
(purple), a carboxy-terminal RING-domain containing protein (Roc1, red), an amino-terminal adaptor protein 
(SKP1, orange), and an F-box containing substrate specificity subunit (light green) with a second protein-protein 
interaction domain with recognizes the target substrate (dark green). SCF activity is enhanced by the conjugation of 
Nedd8 (yellow), a ubiquitin-like molecule, to the cullin backbone.    
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2.0  THE SKP1-CULLIN-F-BOX (SCF) COMPONENT CUL1 IS A CENTROSOMAL 
SUPPRESSOR OF CENTRIOLE MULTIPLICATION 
Work described in this section was published in Cancer Research (Cancer Res. 2009, 69:6668-
6675) with authors Nina Korzeniewski, Leon Zheng, Rolando Cuevas, Joshua Parry, Payel 
Chatterjee, Brittany Anderton, Anette Duensing, Karl Münger and Stefan Duensing 
 
L. Zheng and B. Anderton performed preliminary immunofluorescence and knock-down 
analysis. P. Chatterjee, J. Parry, and R. Cuevas performed several of the western blot 
experiments. N. Korzeniewski performed all other experiments described in this section. A. 
Duensing helped with the experimental design and data analysis. K. Münger and S. Duensing 
conceived the project. N. Korzeniewski and S. Duensing analyzed the results and wrote the 
manuscript. 
 
Work described in this section on CAND1 is in preparation for submission to Molecular Cancer 
with authors Nina Korzeniewski, Anette Duensing and Stefan Duensing. 
 
N. Korzeniewski performed all of the CAND1 experiments. A. Duensing helped with 
experimental design and data analysis. N. Korzeniewski and S. Duensing analyzed the results 
and wrote the manuscript. 
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2.1 INTRODUCTION 
As reviewed in Chapter 1, the single centrosome of a non-dividing cell must duplicate 
once prior to mitosis in order to organize a bipolar mitotic spindle. Centrosome duplication is a 
process which is frequently disrupted in tumor cells, where centrosome overduplication has been 
implicated in mitotic defects, chromosome missegregation and aneuploidy [100-103].  
During a normal centrosome duplication cycle, a single maternal centriole generates one 
and only one daughter centriole. However, recent studies have revealed that proteasomal 
inhibition induces the single maternal centriole to mediate the simultaneous formation of 
multiple daughter centrioles (centriole multiplication) [80]. Given the intrinsic potential of 
maternal centrioles to give birth to multiple daughters, the question arises what the molecular 
mechanisms that normally restrain procentriole formation to only one per cell division cycle may 
be.  
As detailed in the previous chapter, the centrosome has been shown to harbor 
components of the ubiquitin-proteasome machinery including subunits of SCF E3 ubiquitin 
ligases and components of the 26S proteasome [104-107]. Although SCF complexes have been 
implicated in centriole duplication control as well as centriole separation, their precise functions 
have not been fully delineated [92].   
In general, activation of SCF complexes occurs when Nedd8, a ubiquitin-like protein, is 
conjugated (neddylated) on a specific lysine residue located in the carboxy-terminal domain of 
the cullin backbone [108]. This is accomplished by Nedd8 specific E1 and E2 enzymes and Roc1 
[109, 110]. Removal of Nedd8 (deneddylation), and therefore SCF inactivation, is accomplished 
by the COP9 signalosome complex, or CSN (reviewed in [111]).  
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A further mechanism to prevent inappropriate SCF activation is through binding to 
CAND1, a cellular regulatory protein which associates exclusively with deneddylated cullin 
subunits. CAND1 binding to the cullin backbone prevents access of SKP1-F-box protein 
complexes to the cullin core and therefore inhibits formation of the SCF complex [97, 112]. 
Neddylation of CUL1, coupled with substrate availability and formation of the SKP1-F-box 
protein-substrate complex, dissociates CAND1 allowing activation of the SCF-complex to occur 
[113].  
Here, we show that the SCF core component, CUL1, localizes to maternal centrioles and 
that these centrioles serve as assembly platforms for oncogene-induced centriole overduplication. 
Moreover, SCF ubiquitin ligase activity was found to be critically involved in suppressing 
centriole multiplication in human tumor cells by regulating PLK4 protein levels. We provide 
evidence that SCF ubiquitin ligase activity is critical for the activation-dependent degradation of 
PLK4 following overexpression of cyclin E/CDK2, as well as for baseline PLK4 protein 
stability. Furthermore, we show that CAND1, an inhibitor of SCF ligase activity, also localizes 
to maternal centrioles. Overexpression of CAND1 enhanced the ability of PLK4 to induce 
centriole multiplication and stabilized PLK4 protein levels. Collectively, our results suggest that 
SCF ubiquitin ligase activity provides an important mechanism for restraining excessive 
daughter centriole formation at single maternal centrioles and hence centrosome-mediated cell 
division errors and chromosomal instability. Since HPV-16 E7 expression induces centriole 
multiplication in a phenotype reminiscent of CUL1 inactivation, this study provides a framework 
in which to study the molecular mechanism behind HPV-16 E7-induced centriole multiplication. 
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2.2 MATERIALS AND METHODS 
Cell culture, transfections and inhibitor treatments 
U-2 OS or U-2 OS/centrin-GFP cells (centrin-GFP plasmid was kindly provided by 
Michel Bornens, Institut Curie, France [114]) were maintained as previously reported [80]. For 
transient transfections (48 h), pCMV- or pcDNA3-based plasmids encoding c-MYC (kindly 
provided by Philip Leder, Harvard Medical School, Boston, MA), HPV-16 E7, E2F-1 (kindly 
provided by Jacqueline Lees, Massachusetts Institute of Technology, Boston), cyclin E (provided 
by Robert Weinberg through Addgene, Cambridge, MA, USA [115], CDK2 (provided by Sander 
van den Heuvel through Addgene [116], Myc-PLK4 or catalytically inactive Myc-PLK4-D154A 
(kindly provided by Erich A. Nigg (Max Planck Institute of Biochemistry, Martinsried, Germany 
[76]), MYC-CAND1, HA-CUL1, and CUL1 mutant plasmids CUL1-RL, CUL1-DN53, CUL1-
DC22 (kindly provided by Yue Xiong, University of North Carolina, Chapel Hill [112]), 
dominant-negative CUL1 (DN-CUL1; provided by Wade Harper through Addgene [117]) or 
empty vector controls were used and transfected by lipofection (Fugene 6; Roche). Cells were 
co-transfected with a vector encoding red fluorescent protein targeted to mitochondria (DsRED; 
BD Biosciences Clontech, Palo Alto, CA) as transfection marker. Cells were treated with 1 µM 
of the proteasome inhibitor Z-L3VS (Biomol, Plymoth Meeting, PA) or 0.1% DMSO as control. 
To inhibit CDK activity, cells were treated with 1 µM of indirubin-3’-oxime (IO; kindly 
provided by Laurent Meijer, Station Biologique Roscoff, France) or 0.1% DMSO as control. 
Cycloheximide (CHX; Calbiochem, San Diego, CA) was used at 30 µg/ml for the indicated time 
intervals with dH2O as control.     
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Immunological Methods 
Immunoblotting was performed as described previously [80]. Primary antibodies used for 
immunoblotting were directed against CUL1, cyclin E, CDK2, CAND1 (all Santa Cruz, Santa 
Cruz, CA), Myc-tag, (Cell Signaling, Danvers, MA), OctA-Probe/Flag® (Santa Cruz) or actin 
(Sigma, St. Louis, MO).   
Immunofluorescence stainings using CUL1 (Neomarkers, Fremont, CA), γ-tubulin 
(Sigma), CEP170 (Invitrogen, Carlsbad, CA) or PLK4 (mouse monoclonal antibody kindly 
provided by Erich A. Nigg, Max Planck Institute of Biochemistry, Martinsried, Germany) 
antibodies were performed as described previously [80]. Primary antibodies were detected with 
FITC-, Rhodamine Red- or AMCA-conjugated secondary antibodies (Jackson Immunoresearch, 
West Grove, PA) as previously described [80]. 
 
Small interfering RNA (siRNA) 
Synthetic RNA duplexes to reduce CUL1 expression were obtained commercially 
(Ambion, Austin, TX) and used according to manufacturer’s protocol.  
 
Statistical Methods 
 Student’s t test for independent samples was used wherever applicable.  
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2.3 RESULTS 
CUL1-positive maternal centrioles are assembly platforms for oncogene-induced centriole 
overduplication  
To explore the role of SCF ubiquitin ligase activity in centriole biogenesis, an 
immunofluorescence microscopic analysis of the SCF core component CUL1 was performed 
using U-2 OS cells stably expressing centrin-GFP. CUL1 was found to co-localize with the 
centriolar maker centrin (Fig. 6A). The co-localization pattern of CUL1 with centrin-GFP 
suggested that CUL1 may be present at older, mature centrioles (Fig. 6A, middle and bottom 
panels). A co-immunofluorescence microscopic analysis of CUL1 and CEP170, a maker for 
mature maternal centrioles [77], in U-2 OS/centrin-GFP cells revealed that CUL1 in fact 
localizes to older, maternal centrioles (Fig. 6B).  
Overexpression of the HPV-16 E7 oncoprotein has previously been shown to lead to 
excessive daughter centriole formation at maternal centrioles [80, 118]. U-2 OS/centrin-GFP 
cells were transiently transfected with HPV-16 E7, or other oncogenes including c-MYC 
oncogene or the transcription factor E2F-1 followed by immunofluorescence staining for CUL1. 
Since normal centriole duplication generates a maximum of two mature maternal centrioles and a 
maximum of two immature daughters, excessive numbers of CUL1-negative centrioles in the 
presence of one or two CUL1-positive centrioles were counted as abnormal. An increase of cells 
with more than 4 centrioles in the presence of only one or two CUL1-positive centrioles was 
detected in cells overexpressing c-MYC (6.7%), HPV-16 E7 (10.7%, p≤0.05) or E2F-1 (13%, 
p≤0.005) in comparison to empty vector control (3%) (Fig. 6C).  
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Figure 6. CUL1-positive maternal centrioles serve as platforms for oncogene-induced centriole 
overduplication. 
(A) Immunofluorescence microscopic analysis for CUL1 using U-2 OS cells stably expressing centrin-GFP (bottom 
panels). Arrows indicate centrioles shown in inserts. Nuclei stained with DAPI. Scale bar indicates 10 µm. (B) Co-
immunofluorescence microscopic analysis of U-2 OS/centrin-GFP cells for CUL1 and CEP170, a marker for mature 
maternal centrioles. Arrowheads indicate centrioles with co-localization of CUL1 and CEP170 (see also inserts). (C) 
Immunofluorescence microscopic analysis of U-2 OS/centrin-GFP cells for CUL1 following overexpression of E2F-
1. Note overduplication of centrioles in the presence of only two CUL1-positive centrioles (bottom panels). (D) 
Quantification of the proportion of U-2 OS/centrin-GFP cells with centriole overduplication in the presence of one 
or two CUL1-positive centrioles after overexpression of MYC, HPV-16 E7 or E2F-1. Arrows point to centrioles 
shown in inserts. Mean and standard error of three independent experiments with at least 100 cells counted per 
experiment are shown.   
 
These results indicate that the SCF ubiquitin ligase component CUL1 localizes to 
maternal centrioles that serve as assembly platforms for excessive daughter centriole formation 
induced by various oncogenes.  
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Inhibition of SCF ubiquitin ligase activity causes centriole multiplication 
To determine the role of CUL1 in the control of centriole biogenesis, we used siRNA to 
deplete cells of CUL1 and a dominant-negative mutant of CUL1 (DN-CUL1), which has recently 
been shown to effectively reduce CUL1-based SCF activity [119]. SiRNA-mediated knock-down 
of CUL1 led to centriole multiplication with an increase of cells showing multiple daughter 
centrioles at single maternal centrioles (Fig. 7A) from 0.6% in controls to 8.5% in CUL1-
depleted cells (p≤0.05; Fig. 7B, left panel). Centriole multiplication was also detected in cells 
transiently transfected with DN-CUL1 with an increase from 1.3% in controls to 12% in DN-
CUL1-transfected cells (p≤0.05; Fig. 7B, right panel). CUL1 is involved in the degradation of a 
number of critical cell cycle regulators including cyclin E [120, 121]. In line with this notion, we 
detected an increase of cyclin E protein expression in U 2-OS/centrin-GFP cells treated with 
either siRNA against CUL or DN-CUL1 (Fig. 7C). 
These results suggest that cyclin E may contribute to centriole multiplication induced by 
inhibition of CUL1. However, when cyclin E together with its kinase subunit CDK2 was 
overexpressed in U-2 OS/centrin-GFP cells, no significant increase of cells with centriole 
multiplication was detected (Fig. 8A). Only when cyclin E/CDK2 complexes were co-expressed 
with increasing amounts of the centrosomal kinase PLK4, a significant increase of cells with 
centriole multiplication was detected (Fig. 8A,B). Co-expression of PLK4 together with cyclin 
E/CDK2 consistently led to a higher frequency of centriole multiplication than overexpression of 
PLK4 alone (Fig. 8A,B).  
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Figure 7. Inhibition of CUL1 causes centriole multiplication. 
(A) Fluorescence microscopic analysis of U-2 OS/centrin-GFP cells transfected with either control siRNA duplexes 
(siControl) or siRNA targeting CUL1 (siCUL1) for 72 h. A DsRED-encoding plasmid was used as transfection 
marker. Nuclei stained with DAPI. Arrowheads in bottom insert indicate supernumerary daughter centrioles at a 
single mother. Scale bar indicates 10 µm. (B) Quantification of centriole multiplication (>4 centrioles total, >1 
daughter at a single mother) in U-2 OS/centrin-GFP cells transfected with either control (siControl) or CUL1 
(siCUL1) siRNA duplexes for 72 h (left panel) or ectopic expression of empty vector control or DN-CUL1 for 48 h 
(right panel). Mean and standard error of three independent experiments with at least 100 cells counted per 
experiment are shown. Asterisk indicates statistically significant differences (p≤0.05; Student’s t test for 
independent samples). (C) Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells transiently 
transfected with siRNA duplexes targeting CUL1 (siCUL1) or control siRNA (siControl) for the indicated time 
intervals (left panels) or ectopic expression of empty vector control or DN-CUL1 for 48 h (right panel). DN-CUL1 
was detected using an OctA-Probe/Flag® antibody (Santa Cruz). Immunoblot for Actin shows protein loading.   
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Given the known requirements of both cyclin E/CDK2 complexes and PLK4 for efficient 
centriole overduplication and flower formation [76, 80], we asked whether cyclin E/CDK2 
complexes can alter the expression of PLK4 at centrioles. To test this idea, U-2 OS/centrin-GFP 
cells were transiently transfected with cyclin E and CDK2 followed by immunofluorescence 
microscopy for endogenous PLK4 protein (Fig. 8C). In empty vector-transfected control cells, 
disengaged centrioles or duplicated centrioles were associated with a single PLK4 dot that 
typically localized to the site of daughter centriole synthesis at the wall of the maternal centriole 
(Fig. 8C - control). In cells ectopically expressing cyclin E/CDK2, an increased proportion of 
cells with two or more PLK4 dots at single mothers was detected (Fig. 8C - cyclin E/CDK2). 
These PLK4 dots can precede the actual formation of centrin-containing procentrioles (Fig. 8C, 
bottom panels), which is in line with previous results suggesting that PLK4 functions early 
during daughter centriole synthesis [87]. Aberrant PLK4 dots at maternal centrioles were 
detected in 28 out of 52 cells (53.8%) transfected with cyclin E/CDK2 in comparison to 10 out of 
51 cells (19.6%) transfected with empty vector (Fig. 8D). 
Taken together, these results suggest that the centriole multiplication induced by 
inhibition of CUL1 cannot solely be explained by an accumulation of cyclin E but depends also 
on increased levels of PLK4.  
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Figure 8. Ectopic expression of cyclin E/CDK2 does not stimulate centriole multiplication but causes aberrant 
PLK4 recruitment to maternal centrioles. 
(A) Quantification of the proportion of cells with centriole multiplication (>4 centrioles, >1 daughter per maternal 
centriole) after transient transfection with empty vectors (controls) or either cyclin E/CDK2 alone (0 µg PLK4 
plasmid DNA) or increasing amounts of PLK4 alone (grey bars) or a combination of cyclin E/CDK2 with increasing 
amounts of PLK4 plasmid DNA (black bars). Asterisks indicate statistically significant differences (p≤0.05 at 0.5 µg 
and p≤0.005 at 2 µg PLK4 plasmid DNA). (B) Fluorescence microscopic analysis of U-2 OS/centrin-GFP cells after 
transient transfection with empty vector (control) or cyclin E, CDK2 and PLK4. Note the centriole flower in the 
right panel.(C) Immunofluorescence microscopic analysis of U-2 OS/centrin-GFP cells for endogenous PLK4 
expression after transient transfection with either empty vector (control) or cyclin E/CDK2. Arrows indicate an 
aberrant daughter centriole that co-localizes with PLK4 at the maternal centriole. Arrowheads indicate an aberrant 
PLK4 signal at a maternal centriole without a detectable centrin-positive daughter. (D) Quantification of the 
percentage of cells with aberrant (two or more) PLK4 dots at maternal centriole following transfection with empty 
vector (control) or cyclin E/CDK2.  
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PLK4 is degraded by the proteasome and regulated by activation-dependent degradation  
Our findings that cyclin E/CDK2 complexes cause an aberrant recruitment of PLK4 to 
maternal centrioles but do not lead to centriole multiplication unless PLK4 is overexpressed 
suggest that PLK4 levels are rate-limiting for excessive daughter centriole assembly and hence 
are tightly regulated in order to suppress aberrant procentriole assembly. To explore how PLK4 
protein expression is kept at a low level, we first analyzed U-2 OS/centrin-GFP cells ectopically 
expressing PLK4 and treated with the proteasome inhibitor Z-L3VS, which readily stimulates 
centriole multiplication [80].  
 
Figure 9. PLK4 is degraded by the proteasome. 
 (A) Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells transiently transfected with either 
empty vector (control) or PLK4 and treated with 1 µM of the proteasome inhibitor Z-L3VS or 0.1% DMSO at 24 h 
after transfection for an additional 24 h. (B) Immunofluorescence microscopic analysis or U-2 OS/centrin-GFP cells 
treated with 0.1% DMSO or 1 µM Z-L3VS for 48 h and stained for PLK4. Note the excessive amount of PLK4 at 
maternal centrioles of centriole flowers.  
 
Immunoblot analyses revealed a stabilization of ectopically expressed PLK4, together with 
cyclin E, in Z-L3VS-trated cells (Fig. 9A). In addition, Z-L3VS treatment led to an excessive 
amount of endogenous PLK4 at maternal centriole (Fig. 9B). These results indicate that PLK4 
protein levels are, at least in part, regulated by the ubiquitin-proteasome machinery.  
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To further explore why cyclin E/CDK2 can only promote centriole flower formation in 
the presence of excessive amounts of PLK4, PLK4 protein levels were determined by 
immunoblotting after ectopic expression of Myc-tagged PLK4 alone or in combination with 
cyclin E and/or CDK2 (Fig. 10). Surprisingly, we detected a reduction of PLK4 protein levels in 
the presence of ectopically expressed cyclin E or cyclin E/CDK2 (Fig. 10A). Similar results were 
obtained in HeLa cells (not shown). In contrast to wild-type PLK4, protein levels of catalytically 
inactive mutant PLK4 D154A [76] were not significantly decreased in the presence of 
ectopically expressed cyclin E/CDK2 (Fig. 10A).  
 
Figure 10. Cyclin E/CDK2 reduce PLK4 protein stability in a PLK4 kinase activity-dependent manner. 
(A) Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells following transient transfection (48 
h) with empty vector (control), Myc-tagged PLK4, Myc-tagged kinase-inactive mutant PLK4 D154A, cyclin E 
and/or CDK2. Note the decreased protein levels of wild-type PLK4 upon co-transfection with cyclin E or cyclin 
E/CDK2. No such reduction was detected in cells transfected with catalytically inactive mutant PLK4 D154A. 
Immunoblots for Actin are shown to demonstrate protein loading (A-C). (B) Immunoblot analysis of whole cell 
extracts from U-2 OS/centrin-GFP cells after transient transfection Legend is continued on the following page.  
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 (48 h) with PLK4 alone or PLK4 and cyclin E/CDK2 and treatment with 30 µg/ml cycloheximide (CHX) for the 
indicated time intervals. Note the decreased PLK4 protein stability in the presence of ectopically expressed cyclin 
E/CDK2. (C) Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells transiently transfected (24 
h) with empty vector (control) or PLK4 alone or PLK4 in combination with cyclin E/CDK2 and treatment with 1 
µM of the CDK inhibitor indirubin-3’-oxime for 24 h (IO). Note the stabilization of PLK4 protein in IO-treated cells 
in comparison to controls (0.1% DMSO).  
 
Since PLK4 D154A mutant has no apparent defect in its localization to centrioles [76], we 
interpret this finding as evidence that the degradation of PLK4 depends on its activation. Similar 
results have been reported for other protein kinases [122]. The decrease of PLK4 protein levels 
in the presence of cyclin E/CDK2 was due to decreased protein stability as shown by a 
cycloheximide block experiment (Fig. 10B). Furthermore, inhibition of CDK activity using the 
small molecule inhibitor indirubin-3’-oxime (IO) led to a stabilization of PLK4 protein 
underscoring the CDK dependency of this process (Fig. 8C).  
Taken together, these findings suggest cyclin E/CDK2 promote the aberrant recruitment 
of PLK4 to maternal centrioles followed by its activation-dependent degradation. This process 
may prevent the accumulation of active PLK4 at maternal centrioles at levels that may promote 
aberrant procentriole assembly. Our finding that additional PLK4 dots at maternal centrioles are 
often weaker in signal intensity than normal endogenous PLK4 dots (Fig. 10C) lends support to 
this notion.  
 
CUL1 regulates PLK4 protein stability 
We next asked whether CUL1 contributes to the regulation of PLK4 protein levels. 
Ectopic expression of DN-CUL1 caused an excess of endogenous PLK4 at maternal centrioles 
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(Fig. 11A, left panels) that was phenotypically similar to PLK4 accumulation in response to Z-
L3VS-associated inhibition of proteasomal PLK4 degradation. To accurately assess this increase, 
the integrated density of PLK4 signals at maternal centrioles was quantified using ImageJ and 
expressed in arbitrary units (http://rsbweb.nih.gov/ij/; Fig. 11A, right panels). Control cells in 
which a maternal centriole organized the formation of a single daughter (n=32) had a mean 
integrated signal density of PLK4 of 599 at the mothers. In cells with flower formation after 
transfection with DN-CUL1 (n=29, average number of daughters = 4.2), the mean integrated 
PLK4 signal density was significantly increased to 4,114 (p≤0.001). This value was significantly 
higher than expected if each daughter was associated with the amount of PLK4 detected in 
control cells (4.2 x 599 = 2,516) thus underscoring that DN-CUL1 indeed leads to an excessive 
level of PLK4 protein at maternal centrioles. 
We tested next the effects of DN-CUL1 on cyclin E/CDK2-induced PLK4 degradation. 
Using immunoblotting, we found that DN-CUL1 abrogates the reduction of PLK4 protein levels 
associated with ectopic expression of cyclin E/CDK2 (Fig. 11B). DN-CUL1 also increased the 
baseline protein stability of ectopically expressed PLK4 in the absence of overexpressed cyclin 
E/CDK2 (Fig. 11C). Depletion of CUL1 by siRNA led to similar results (not shown).  
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Figure 11. CUL1 regulates PLK4 protein stability. 
(A) Immunofluorescence microscopic analysis of U-2 OS/centrin-GFP cells for PLK4 at 48 h after transfection of 
empty vector (control) or DN-CUL1. Note the excessive amount of PLK4 in the bottom panels. Quantification of the 
integrated density of PLK4 signals at maternal centrioles in U-2 OS/centrin-GFP cells transfected with empty vector 
or DN-CUL1 for 48 h. Asterisk indicates statistically significant differences (p≤0.001; Student’s t test for 
independent samples). (B) Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells after transient 
transfection (48 h) with empty vectors (control) or PLK4 in combination with either cyclin E/CDK2 alone or cyclin 
E/CDK2 and DN-CUL1. Note the increase of PLK4 protein in the presence of DN-CUL1 in the last lane. (C) 
Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells after transient transfection with empty 
vectors (control) or dominant-negative CUL1 (DN-CUL1) for 48 h followed by transfection with Myc-PLK4 for 24 
h and treatment with 30 µg/ml cycloheximide (CHX) for the indicated time intervals. Note the increased protein 
stability of Myc-PLK4 in the presence of DN-CUL1 (6 h CHX, last lane).  
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Taken together, these results suggest that CUL1 is involved in both cyclin E/CDK2-
associated degradation of PLK4 and baseline PLK4 protein stability.   
 
CAND1, an inhibitor of SCF-ligase activity, localizes to maternal centrioles and stabilizes 
PLK4 protein 
We have shown that inhibition of SCF complexes leads to centriole multiplication (Fig. 
7A) To further explore the importance of SCF activity in maintaining centriole duplication 
control we examined the role of CAND1, an inhibitor of SCF ligase activity, in restraining 
centriole biogenesis. We first asked whether CAND1 localizes to the centrosomes utilizing U-2 
OS/centrin-GFP cells. We found that CAND1 localizes to centrioles in a throughout the cell 
division cycle (Fig. 12A). Further, we determined that CAND1 co-localizes with CUL1 in U-2 
OS/centrin-GFP cells (Fig. 12B). We next discovered that CAND1, similar to CUL1, localized 
predominantly to older, mature centrioles as evidenced by co-localization with CEP170 a marker 
of mature centrioles (Fig. 12C).  
Based on these observations, we asked whether ectopic expression of CAND1 would 
induce centriole multiplication. We found a modest but significant increase in centriole 
multiplication from 0.5% in controls to 1.5% in CAND1-transfected cells (p< 0.05) (Fig. 12D). 
Due to the fact that centriole multiplication was induced by ectopic expression of CAND1, we 
asked if CAND1 can modulate PLK4 function. We expressed CAND1 in U-2 OS/centrin-GFP 
cells for 24 h and then transfected cells with increasing amounts of PLK4 for a further 24 h and 
assayed for centriole multiplication. We found that cells which co-expressed CAND1 and PLK4 
together consistently exhibited an enhancement of centriole multiplication over that seen with 
ectopic expression of PLK4 alone (Fig. 12E, black bars).   
 38 
 
Figure 12. CAND1, an inhibitor of CUL1-based ligase activity, localizes to centrioles and regulates PLK4 
stability. 
 (A) Immunofluorescence microscopic analysis of CAND1 throughout the cell cycle using U-2 OS cells stably 
expressing centrin-GFP. Arrows indicate centrioles shown in inserts. Legend is continued on the following page.  
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Nuclei stained with DAPI. Scale bar indicates 10 µm. (B) Co-immunofluorescence microscopic analysis of U-2 
OS/centrin-GFP cells for CAND1 and CEP170 a marker of mature maternal centrioles. Arrowheads indicate 
centrioles with co-localization of CAND1 and CEP170 (see also inserts). (C) Co-immunofluorescence microscopic 
analysis of U-2 OS/centrin-GFP cells for CAND1 and CUL1. Arrowheads indicate centrioles with co-localization of 
CAND1 and CUL1 (see also inserts). (D) Quantification of centriole multiplication (>4 centrioles total, >1 daughter 
at a single mother) in U-2 OS/centrin-GFP cells ectopically expressing either a control plasmid or Myc-CAND1 for 
48 h (left panel) Mean and standard error of two independent experiments with at least 100 cells counted per 
experiment are shown. Asterisk indicates statistically significant differences (p≤0.05; Student’s t test for 
independent samples). (E) Immunoblot analysis of whole cell extracts from U-2 OS/centrin-GFP cells after transient 
transfection with empty vectors (control), Myc-CAND1, Myc-PLK4 for 48 h and treatment with 60 µg/ml 
cycloheximide (CHX) for the indicated time intervals. Note the increased protein stability of Myc-PLK4 in the 
presence of Myc-CAND1 (6 h CHX, last lane). (F) Quantification of the proportion of cells with centriole 
multiplication (>4 centrioles, >1 daughter per maternal centriole) after transient transfection with empty vectors 
(controls) or CAND1 alone (0 µg PLK4 plasmid DNA) or increasing amounts of PLK4 alone (grey bars) or a 
combination of CAND1 with increasing amounts of PLK4 plasmid DNA (black bars). Asterisks indicate statistically 
significant differences (p≤0.05 at 0.1 ?g and p≤ 0.001 at 0.5 µg PLK4 plasmid DNA). 
 
Finally, we asked if CAND1 plays a role in the regulation of PLK4 protein levels. 
Performing a cycloheximide block experiment, we found that ectopic expression of CAND1 
stabilized PLK4 protein levels without affecting CUL1 stabilization (Fig. 12F). Together, these 
results suggest that CAND1 overexpression modulates PLK4 half-life thereby promoting 
centriole multiplication.  
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2.4 DISCUSSION 
Results presented in Chapter 2 of this thesis show that the core SCF ubiquitin ligase 
component CUL1 is critical to tightly regulate PLK4 protein levels in order to suppress aberrant 
centriole biogenesis at maternal centrioles.  
Upregulation of PLK4 expression is an extremely powerful stimulus for centriole 
multiplication [80, 87, 98, 99]. The fact that overexpression of cyclin E/CDK2 can aberrantly 
recruit PLK4 to maternal centrioles (Fig. 8C) provides mechanistic insight how CDK2 and PLK4 
cooperate to stimulate excessive daughter centriole formation [76, 80]. Our finding that 
overexpression of cyclin E/CDK2 leads to the degradation of PLK4 in a PLK4 kinase activity-
dependent manner explains why cyclin E/CKD2 alone is not sufficient to trigger centriole 
multiplication. The low endogenous levels of PLK4 together with the activation-dependent 
degradation of PLK4 hence likely represent cellular failsafe mechanisms to limit normal 
centriole biogenesis to one per cell division cycle.  
We were not able to demonstrate a direct interaction between CDK2 and PLK4 by co-
immunoprecipitation (data not shown) suggesting that the association is either transient or 
indirect. Whether any of the reported centrosomal CDK2 targets such as nucleophosmin, CP110 
or MPS1 play a role in this process remains to be determined [123-126].  
The question whether normal activation of cyclin E/CDK2 complexes triggers PLK4 
recruitment during undisturbed, normal centriole duplication also remains to be determined. It is 
interesting to note, however, that CDK2 deficient MEFs cells have no detectable defects in 
centrosomal duplication [127]. Oncogene-triggered centrosome overduplication, however, was 
clearly blocked in CDK2-deficient cells [127] suggesting that deregulation of CDK2, as 
frequently seen in tumors, may promote centriole overduplication by aberrantly recruiting PLK4. 
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One prediction from our results is that such tumor cells may also harbor alterations of the PLK4 
degradation machinery. Moreover, oncogenic stimuli that induce centriole overduplication may 
not only function by deregulation cyclin E/CDK2 activity but also by impacting on CUL1-based 
SCF ubiquitin ligase activity (Fig. 11D).  
A possible mechanism for such inhibition may be the CUL1 neddylation cycle or the 
association/dissociation with the CUL1 inhibitor CAND1 (Fig. 12C) [112]. Association with 
CAND1, unlike the neddylation cycle, modulates SCF-mediated proteolytic activity through 
enhancing the rate of SCF-complex turnover. Paradoxically, CAND1 has been shown to both in 
vitro inhibit and in vivo activate SCF complexes [94]. Two mechanisms have been proposed to 
reconcile these observations. The CUL1 backbone is the rate-limiting factor in SCF complex 
assembly, as there are over 76 different human F-box proteins currently classified [128]. F-box 
proteins must complete for binding to the stable CUL1 core and are known to auto-ubiquitinate, 
promoting their own degradation [94, 129, 130]. It has been proposed that CAND1 association 
with CUL1 may protect F-box proteins from auto-ubiquitination promoting the efficient 
assembly of SCF complexes [96]. The second proposal hypothesizes that CAND1 may actually 
alter the composition of SCF-ligase complexes enhancing the incorporation of particular F-box 
proteins over others [113]. Our results have shown that overexpression of CAND1 induces a 
small, but significant, amount of centriole multiplication and modulates PLK4 protein stability 
(Fig 13E, F). Determining the F-box responsible for PLK4 degradation in human cells will 
provide mechanistic insight into exactly how CAND1 may regulate SCF activity at maternal 
centrioles.    
Two recent studies in Drosophila cells have demonstrated a role of the SCF/Slimb 
ubiquitin ligase in the regulation of SAK (PLK4) [99, 131]. Results shown here extend these 
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findings by substantiating the involvement of SCF ubiquitin ligase complexes in PLK4 
regulation in human cells, showing that PLK4 functions as a nexus between the cell cycle engine 
and the ubiquitin/proteasome machinery. Slimb is the ortholog of the mammalian F-box protein 
β-TrCP and although knock-out of β-TrCP in mice has been found to lead to centrosome 
amplification [132], our own experiments did not show significant centriole multiplication after 
siRNA-mediated knock-down of β-TrCP in human U-2 OS cells (not shown). This finding does 
not preclude a role of SCFβ-TrCP in PLK4 regulation in human cells but it raises the interesting 
possibility that there may be cell type specific differences in PLK4 regulation and/or that more 
than one F-box protein participates in SCF-mediated regulation of PLK4 stability in a spatio-
temporally controlled manner. Further experiments to explore this possibility in activation-
dependent versus baseline PLK4 degradation by CUL1 shown here are clearly warranted. Given 
the need to tightly regulate PLK4 levels, it is likely that multiple mechanisms converge on PLK4 
expression control and protein stability.  
The results described here have major implications for the potential mechanism by which 
the HPV-16 E7 oncoprotein induces centriole multiplication. The high-risk HPV-16 E7 protein is 
known to deregulate cyclin E/CDK2 complexes and has been show to localize to the centrosome 
[50, 82, 133]. Whether HPV-16 E7 also deregulates PLK4 protein expression or interferes with 
SCF-mediated proteolytic control at maternal centrioles is the subject of the following chapter.   
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3.0  THE HPV-16 E7 ONCOPROTEIN INDUCES CENTRIOLE MULTIPLICATION 
THROUGH DISRUPTION OF PLK4 
3.1 INTRODUCTION 
As detailed in Chapter 1 of this thesis, expression of the high-risk HPV-16 E7 
oncoprotein promotes genomic instability through the rapid disruption of centriole duplication 
control. This rapid induction of centriole overduplication occurs through the simultaneous 
formation of multiple daughter centrioles at single maternal centrioles (centriole multiplication). 
The exact cellular components that HPV-16 E7 targets to promote centriole multiplication are 
currently unknown. 
Results described in Chapter 2 of this thesis, revealed that several molecular players 
involved in the centriole multiplication pathway were recently determined. We discovered that 
CDK2, cyclin E, and PLK4 were necessary factors for centriole multiplication [80]. Ectopic 
expression of CDK2/cyclin E alone, despite its ability to mediate the aberrant recruitment of 
PLK4, was not sufficient to induce centriole multiplication. This only occurred when PLK4 was 
upregulated, suggesting that PLK4 protein levels are rate-limiting for centriole multiplication 
[134].  
High-risk HPV-16 E7 protein expression is known to deregulate cyclin E/CDK2 
complexes [50, 133]. Whether HPV-16 E7 also deregulates PLK4 protein expression had not 
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been determined. However, previous studies have shown that an HPV-16 E7 mutant deficient in 
pRB binding and degradation is unable to promote centriole overduplication [81]. This 
observation suggested that disruption of pRB signaling may be important in the ability of high-
risk HPV-16 E7 to either target or disrupt the molecular players involved in activation of the 
centriole multiplication pathway. 
PLK4 is an essential regulator of both centriole duplication and cell viability [76, 135]. 
Deregulation of PLK4 by overexpression, depletion via epigenetic silencing or loss of 
heterozygosity (LOH) has been associated with chromosomal instability and malignancy [76, 
136]. These observations suggest that a strict control of PLK4 transcript and protein levels is 
necessary to maintain cell viability and that changes in PLK4 regulation are detrimental to 
genomic integrity.  
We report here that the PLK4 protein is aberrantly recruited to maternal centrioles in 
primary human keratinocytes engineered to stably express HPV-16 E7. Real-time quantitative 
reverse transcriptase (qRT-PCR) demonstrated an increase in PLK4 transcription in 
keratinocytes stably expressing HPV-16 E7. A mutational analysis revealed that the ability of 
HPV-16 E7 to upregulate PLK4 mRNA was found to be dependent on its ability to degrade pRB 
and inactivate HDACs, suggesting a role for E2F-mediated gene transcription in deregulation of 
PLK4. Collectively, these results highlight the critical role of PLK4 as a regulator of centriole 
biogenesis and identify PLK4 as a novel target for small molecules to prevent centriole 
abnormalities, mitotic infidelity and malignant progression in HPV-associated neoplasms. 
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3.2 MATERIALS AND METHODS 
Cell culture, transfections and inhibitor treatments 
U-2 OS/centrin-GFP cells (centrin-GFP plasmid was kindly provided by Michel Bornens, 
Institut Curie, France [114]) were maintained as previously reported [80]. Normal immortalized 
human keratinocytes (NIKs) engineered to stably express a control plasmid, LXSN, or HPV-16 
E7 (generous gift of Susanne Wells, Cincinnati Children’s Hospital Medical Center) were 
maintained in serum-free keratinocyte growth medium (Epilife; Cascade 
Biologics/Invitrogen) supplemented with human keratinocyte growth supplement (Invitrogen), 50 
units/mL penicillin (Cambrex), 50 µ g/mL streptomycin (Cambrex), and fungizone 
(Invitrogen). For transient transfection of U-2 OS/centrin-GFP cells (48 h), pCMV-based 
plasmids encoding HPV-16 E7, HPV-16 E7 Δ21-24, HPV-16 E7 L67R (kindly provided by Karl 
Münger, The Channing Laboratory, Brigham and Women’s Hospital, Boston, MA), HPV-6 E6, 
HPV-6 E7 (LXSN-based low risk HPV-6 E6 and HPV-6 E7 constructs were kindly provided by 
Denise Galloway (Fred Hutchinson Cancer Research Center, Seattle, WA) and sucloned into 
pCMV-based vectors [137]) or empty vector controls were used and transfected by lipofection 
(Fugene 6; Roche). Cells were co-transfected with a vector encoding red fluorescent protein 
targeted to mitochondria (DsRED; BD Biosciences Clontech, Palo Alto, CA) as a transfection 
marker. For transient transfection (48h) of NIK cells, centrin-GFP was used and transfected 
utilizing nucleofection (Amaxa).  
 
Immunological Methods 
Immunofluorescence staining using PLK4 (mouse monoclonal antibody kindly provided 
by Erich A. Nigg, Max Planck Institute of Biochemistry, Martinsried, Germany) or centrin 
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(mouse monoclonal antibody kindly provided by Jeffrey L. Salisbury, Mayo Clinic, Rochester, 
MN) antibody was performed as described previously [80]. Primary antibody was detected with 
either Rhodamine Red- or FITC-conjugated secondary antibody (Jackson Immunoresearch, West 
Grove, PA) as previously described [80]. 
 
Quantitative reverse-transcriptase real-time polymerase chain reaction (qRT-PCR) 
RNA was extracted using the RNase Easy kit (Qiagen, USA). DNase I-treated total RNA 
(500 ng) was subjected to qRT-PCR analysis using the one step QuantiTect SYBR Green RT-
PCR Master Mix (Qiagen, USA) and the Real-Time thermocycler iQ5 (BioRad, USA). For qRT-
PCR analysis of PLK4 mRNA, the following primer was used: forward 5′-
AGTGCTCCCTTTTTCCCAAT-3′ and reverse 5′-AGCAGCACTATGCATGACCA-3′ (147-bp 
product). The primer sequences for the control housekeeping β-actin used was: forward 5′-
TGCGCAGAAAACAAGATGAG-3′ and reverse 5′-CACCTTCACCGTTCCAGTTT-3′ (113-bp 
product). All reactions were done in triplicate and relative expression of RNAs was calculated 
using the ΔΔCT method [138]. 
 
Statistical Methods 
Student’s t test for independent samples was used to calculate statistical significance of 
centriole counts. Chi-square test was used to determine the statistical significance of aberrant 
PLK4 recruitment to maternal centrioles in NIK cells.   
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3.3 RESULTS 
PLK4 is aberrantly recruited to maternal centrioles in HPV-16 E7 expression cells 
It was recently discovered that deregulation of cyclin E/CDK2 led to the aberrant 
recruitment of PLK4 to maternal centrioles and that PLK4 protein level is the rate-limiting step 
in the centriole multiplication pathway [134]. We therefore examined if HPV-16 E7 expression 
resulted in the aberrant recruitment of PLK4 protein to maternal centrioles. Non-transformed 
normal immortalized human keratinocytes (NIKs) engineered to stably express either a control 
plasmid, LXSN, or HPV-16 E7 were transiently transfected with a centrin-GFP plasmid as a 
marker of centrioles followed by immunofluorescence microscopy for endogenous PLK4. In 
control LXSN-expressing cells, disengaged centrioles were associated with a single dot of 
endogenous PLK4 that localized to the site of daughter centriole synthesis at the wall of maternal 
centrioles (Fig. 13A, NIK LXSN). In NIKs stably expressing HPV-16 E7 an increased 
proportion of cells with two or more dots of endogenous PLK4 at single mothers was detected 
(Fig. 13A, NIK HPV-16 E7). These aberrant PLK4 dots were occasionally found to precede the 
formation of daughter centrioles, as previously noted [134]. Aberrant PLK4 dots at maternal 
centrioles were detected in 29 of 86 (33.7%) cells expressing the control plasmid LXSN (Fig. 
13B). Stable expression of HPV-16 E7 led to aberrant PLK4 expression at 45 of 89 (50.6%) of 
NIKs (p<0.05). 
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Figure 13. Stable expression of HPV-16 E7 leads to the aberrant recruitment of PLK4 to maternal centrioles. 
(A) Immunofluorescence microscopic analysis of NIKs transiently transfected with centrin-GFP (48 h) for 
endogenous PLK4 expression. Arrows indicate an aberrant PLK4 signal at a maternal centriole. (B) Quantification 
of the percentage of cells with aberrant (two or more) PLK4 dots at maternal centrioles in NIKs stably expressing 
either a control plasmid, LXSN, or HPV-16 E7. Asterisks indicate statistically significant differences (p≤0.05). 
 
These results suggest that HPV-16 E7 expression leads to the aberrant recruitment of 
PLK4 to maternal centrioles. 
 
HPV-16 E7 expression upregulates PLK4 mRNA levels  
Previous results have shown that aberrant recruitment of endogenous PLK4 protein was 
insufficient to induce centriole multiplication. A concomitant increase in PLK4 protein level was 
needed for centriole multiplication to occur [134]. The aberrant recruitment of PLK4 to maternal 
centrioles is recapitulated in cells stably expressing HPV-16 E7 (Fig. 13A). We next asked if 
these cells also exhibited centriole overduplication.  Stable expression of HPV-16 E7 in NIKs led 
to a statistically significant increase in centriole overduplication from 3.6% in control LXSN 
expressing cells to 8.3% in HPV-16 E7 expressing cells (p<0.05) (Fig. 14A-B). This result 
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suggests that the aberrant recruitment of PLK4 protein to maternal centrioles in cells stably 
expressing HPV-16 E7 may promote centriole overduplication and that PLK4 protein levels may 
be increased in these cells. 
We next wanted to determine if NIKs stably expressing HPV-16 E7 deregulated PLK4 
expression to ultimately enhance PLK4 protein levels at maternal centrioles. One of the most 
important functions of the HPV E7 oncoprotein is to disrupt cellular gene transcription. The 
PLK4 promoter is known to contain E2F-responsive elements leading to the hypothesis that 
HPV-16 E7 expression may increase PLK4 gene transcription [139]. To test this, we performed 
real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) of PLK4 
mRNA in NIKs stably expressing either a control plasmid, LXSN, or HPV-16 E7. We found that 
stable expression of HPV-16 E7 led to a small (1.25-fold) increase in PLK4 mRNA over control 
LXSN-expressing cells (Fig. 14C).  
These results indicate that stable expression of HPV-16 E7 in non-transformed cell leads 
to upregulation of PLK4 mRNA which may promote PLK4 protein accumulation at maternal 
centrioles.  
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Figure 14. NIKs stably expressing HPV-16 E7 exhibit centriole overduplication and upregulate PLK4 mRNA.  
(A) Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) for PLK4 was performed on 
total RNA isolated from NIKs expressing either a control plasmid, LXSN, or HPV-16 E7. β−actin was used as a 
control housekeeping gene. Experiments were performed in triplicate and analyzed as described in the materials and 
methods section. (B) Immunofluorescence and quantification of NIKs stably expressing either a control plasmid, 
LXSN, or HPV-16 E7 exhibiting >4 centrioles. Centrioles in NIKs were visualized by staining with centrin 
antibody. Asterisks indicate statistically significant differences (p≤0.05). 
 
Upregulation of PLK4 mRNA by HPV-16 E7 is pRB- and HDAC-dependent 
We next explored which functional domain of HPV-16 E7 was responsible for 
upregulation of PLK4 mRNA. We transiently transfected U-2 OS/centrin-GFP cells with various 
HPV-16 E7 mutant constructs and isolated total RNA to perform qRT-PCR of PLK4 mRNA. 
Similar to stable expression in NIKs, transient expression of HPV-16 E7 led to a small (1.7 fold) 
increase in PLK4 mRNA (Fig. 15A). An HPV-16 E7 mutant with deletion of the amino acid 
region 21-24 which contains the LCXCE motif (HPV-16 E7 Δ21-24) and is deficient in pRB 
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binding was unable to upregulate PLK4 mRNA [42, 140] (Fig. 15A). Further, an HPV-16 E7 
amino acid substitution mutant L67R (HPV-16 E7 L67R) which is incapable of interaction with 
histone deacetylases (HDACs) was also deficient in modulating PLK4 mRNA level (Fig. 15A). 
 
Figure 15. The ability of HPV-16 E7 to upregulate PLK4 mRNA is both pRB- and HDAC-dependent. 
 (A) Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) for PLK4 was performed on 
total RNA isolated from U 2-OS/centrin-GFP cells transiently expressing either an empty vector control (Control), 
HPV-16 E7, mutant HPV-16 Δ21-24 or mutant HPV-16 E7 L67R. β-actin was used as a control housekeeping gene. 
Experiments were performed in triplicate and analyzed as described in the materials and methods section. (B) 
Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) for PLK4 was performed on total 
RNA isolated U 2-OS/centrin-GFP cells transiently expressing either an empty vector control (Control), HPV-6 E7, 
HPV-6 E6, or HPV-16 E6. β-actin was used as a control housekeeping gene. Experiments were performed in 
triplicate and analyzed as described in the materials and methods section. 
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Importantly, PLK4 mRNA level was not increased following transient expression of low-risk 
HPV-6 E7, high-risk HPV-16 E6 or low-risk HPV-6 E6 (Fig. 15B). 
Together, our results suggest that the induction of centriole multiplication by the HPV-16 
E7 oncoprotein relies, at least in part, on the upregulation of PLK4 mRNA in both a pRB- and 
HDAC-dependent manner. 
 
The ability of HPV-16 E7 to induce centriole overduplication correlates with upregulation 
of PLK4 mRNA 
We next analyzed whether the ability of the HPV-16 E7 oncoprotein to upregulate PLK4 
mRNA correlated with the capacity to induce centriole overduplication. Transient expression in 
U-2 OS/centrin GFP cells led to an increase in centriole overduplication from 1% in control 
transfected cells to 6.5% in HPV-16 E7 transfected cells (p<0.001; Fig 16A-B). Expression of 
HPV-16 E7 Δ21-24 completely abolished the ability of the E7 oncoprotein to induce centriole 
overduplication, as has been previously reported (Fig. 16); [72, 81]). Interestingly, expression of 
HPV-16 E7 L67R led to a 1.3-fold (2.3%) increase in cells exhibiting centriole overduplication 
compared to control transfected cells (Fig. 16B). In conclusion, upregulation of PLK4 mRNA 
correlates with the ability of HPV-16 E7 to promote centriole overduplication. 
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Figure 16. Enhancement of PLK4 mRNA by HPV-16 E7 mutant constructs correlates with their ability to 
induce centriole overduplication.   
(A) Fluorescence microscopic analysis of U-2 OS/centrin-GFP cells transfected with either an empty vector control 
plasmid (Control) or HPV-16 E7 for 48 h. A DsRED-encoding plasmid was used as transfection marker. Nuclei 
stained with DAPI. Scale bar indicates 10 µm. (B) Quantification of centriole overduplication (>4 centrioles) in U-2 
OS/centrin-GFP cells ectopically expressing either a control plasmid, HPV-16 E7, mutant HPV-16 Δ21-24 or 
mutant HPV-16 E7 L67R for 48 h. Mean and standard error of two independent experiments with at least 100 cells 
counted per experiment are shown. Asterisk indicates statistically significant differences (p≤0.001; Student’s t test 
for independent samples). 
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3.4 DISCUSSION 
Results described here suggest a mechanism for the rapid induction of centriole 
multiplication by the HPV-16 E7 oncoprotein. It has previously been shown that cyclin E/CDK2 
mediated the aberrant recruitment of PLK4 to maternal centrioles. However a concurrent 
increase in PLK4 protein was necessary for centriole multiplication to occur suggesting that the 
early steps of daughter centriole synthesis are reversible. We discovered that the aberrant 
recruitment of PLK4 to maternal centrioles is recapitulated in cells stably expressing HPV-16 E7 
and that these cells contained increased PLK4 mRNA transcripts.  
The increase in PLK4 mRNA, albeit only modest, may be necessary to promote the 
aberrant recruitment of excess PLK4 to maternal centrioles in the form of multiple PLK4 dots 
and ultimately centriole multiplication. Support for this notion comes from a previous study 
which determined that ongoing RNA polymerase II transcription is necessary for HPV-16 E7 
induced centriole overduplication but dispensable for normal centriole duplication [141]. 
Although we do not know if PLK4 transcription is RNA polymerase II dependent, this is in line 
with our finding that increased PLK4 mRNA transcripts play a role in HPV-16 E7-induced 
centriole multiplication. However, further experiments utilizing siRNA against PLK4 in HPV-16 
E7 expressing cells are necessary to confirm this hypothesis.  
The PLK4 promoter has been shown to contain E2F-responsive elements and be 
repressed by HDACs [142]. In line with this, we found that the HPV-16 E7 Δ21-24 mutant 
which is incapable of pRB-binding was unable to upregulate PLK4 mRNA and, in accordance 
with previous studies, unable to promote centriole overduplication [81]. Although the HPV-16 
E7 Δ21-24 mutant, is unable to bind and degrade pRB, it is still capable of interacting with 
HDACs [42]. However, this interaction may be irrelevant in this context as derepression of E2F-
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gene promoters would not automatically increase their transcriptional expression without a 
concurrent disruption of the pRB signaling axis.  
Like the HPV-16 E7 Δ21-24 mutant construct, the HDAC deficient mutant L67R was 
also unable to upregulate PLK4 mRNA. The HPV-16 L67R mutant is still capable of interacting 
with pRB although it does so less efficiently and has a reduced capacity to activate E2F-
dependent transcription [44, 140]. This defect complicates analysis of the role of HDACs in the 
HPV-16 E7-induced modulation of PLK4 mRNA levels. Analyzing PLK4 mRNA abundance in 
HPV-16 E7 expressing cell which are deficient in HDACs or pRB-family members would clarify 
the role of HDACs in the HPV-16 E7–mediated modulation of PLK4 mRNA. 
However, unlike the pRB-binding deficient mutant, the HPV-16 L67R mutant was still 
able to induce a small but significant increase in centriole overduplication. This may be 
explained by the fact that the pRB-binding region within Δ21-24 has been implicated in HPV-16 
E7 mediated pRB-independent promotion of centriole overduplication [82]. The small amount of 
centriole overduplication seen following HPV-16 E7 L67R may be due to this pRB-independent 
mechanism. There are several reports suggesting that mutations in the zinc-finger domain of 
HPV-16 E7 result in reduced protein stability [43, 140]. Decreased protein stability of HPV-16 
L67R compared to wild-type HPV-16 E7 may be a further reason why this mutant construct did 
not induce a more significant amount of centriole overduplication.  
An alternative, although not mutually exclusive, mechanism of HPV-16 E7-mediated 
increase in PLK4 protein levels is modulation of the proteolytic control system localized at 
maternal centrioles responsible for regulating PLK4. Experiments described in Chapter 2 of this 
thesis demonstrated that CUL1, the core component of SCF ubiquitin ligase complexes, localizes 
to the maternal centriole and regulates PLK4 protein levels to restrain centriole biogenesis [134]. 
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This leads to the question of why excess PLK4 protein recruited to maternal centrioles in HPV-
16 E7 expressing cells is not degraded by this proteolytic system to prevent centriole 
multiplication. HPV-16 E7 has been shown to localize to the centrosome and may locally 
influence the activity of SCF complexes at maternal centrioles. There is one report, which has 
been challenged, suggesting that the HPV-16 E7 oncoprotein may directly interact with CUL1 
[35, 143]. The CUL1 inhibitor CAND1 has also been implicated in regulation of PLK4 stability 
(see Chapter 2). Whether CAND1 protein levels are increased in HPV-16 E7 expressing cells, 
possibly dampening the proteolytic response to excess PLK4 protein recruitment and promoting 
the accumulation of PLK4 protein levels, remains to be determined.  
PLK4 is essential in order to maintain both centriole duplication control and cell viability. 
Interestingly, the PLK4 locus has not been definitively implicated in a human malignancy [136]. 
This may be due to the fact that any large scale change in PLK4 level, be it overexpression or 
insufficiency, is lethal to the cell [136]. This emphasizes that only small changes in PLK4 
protein level would be tolerable to the cell and could possibly promote a sub-lethal level of 
genomic instability setting the stage for malignant progression [76, 136].  
We have previously shown that overexpression of minute amounts of PLK4 still leads to 
a significant increase in centriole multiplication (Chapter 2; [134]. This illustrates that slight 
changes in PLK4 protein levels, as may occur following the moderate increase in PLK4 mRNA 
level induced by HPV-16 E7 expression or through potential dampening of the proteolytic 
response at maternal centrioles, may constitute a large enough change to promote centriole 
multiplication in HPV-16 E7 expressing cells.   
 57 
Collectively, these results highlight the critical role of PLK4 as a regulator of centriole 
biogenesis and identify PLK4 as a novel target for small molecules to prevent centriole 
abnormalities,   mitotic  infidelity   and  malignant   progression  in pre-invasive  HPV-associated 
neoplasms. 
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4.0  DAUGHTER CENTRIOLE ELONGATION IS CONTOLLED BY 
PROTEOLYSIS 
A revised manuscript of the work described in this section has been submitted to Molecular 
Biology of the Cell with authors Nina Korzeniewski, Anette Duensing, and Stefan Duensing 
 
N. Korzeniewski performed all experiments described in this section. A. Duensing helped with 
the experimental design and data analysis. N. Korzeniewski and S. Duensing conceived the 
project, analyzed the results and wrote the manuscript. 
4.1 INTRODUCTION 
While we were examining HPV-16 E7 expressing cells for centriole duplication defects 
we observed a small percentage of cells (~1%) with elongated centrioles (data not shown) which 
we never saw in control cells. This was intriguing because the HPV-16 E7 oncoprotein is known 
to manipulate CUL2-containing ubiquitin ligase complexes, replacing the VHL adaptor protein 
to direct the atypical degradation of pRB [35]. VHL-containing E3 ubiquitin ligases have been 
implicated in cilia maintenance [144]. We hypothesized that modulation of VHL-containing 
complexes by HPV-16 E7 expression might induce a small number of cycling cells to aberrantly 
form primary cilia. The rational for this hypothesis was further strengthened by the recent 
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discovery that depletion of two centriolar proteins, Cep97 and CP110, led to the inappropriate 
formation of primary cilia in non-quiescent cells [145]. In many vertebrate cells that have exited 
the cell cycle and are not actively proliferating, the centriole pair will migrate to the cell surface 
where the maternal centriole forms a basal body that organizes the elongation and formation of a 
primary cilium [146]. The primary cilium plays an important role as a cellular sensor providing a 
signaling platform that modulates both cell cycle progression and cellular differentiation [146]. 
Cilia dysfunction is associated with several human diseases classified as “ciliopathies” and has 
also been linked to the development of cancer [147].  
Determining what proteins are involved in centriolar elongation, a key step in cilia 
formation, may aid in determining how and why cilia dysfunctions arise possibly contributing to 
their therapeutic prevention.           
Besides recent studies implicating the centriolar protein CPAP, and the previously 
identified cilia-suppressive functions of Cep97 and CP110, little is currently about how centriole 
length is controlled [145, 148-150]. Daughter centriole elongation begins during S-phase of the 
cell cycle and centrioles reach approximately 80% the length of the maternal centriole in late-G2 
[151]. The daughter centriole reaches the full length of the maternal centriole, but normally not 
beyond, during the following cell cycle [73]. The mechanism(s) preventing the daughter 
centriole from elongating to a longer length than the maternal centriole are unknown.  
We found that treatment of U-2 OS/centrin-GFP cells with the proteasome inhibitor Z-
L3VS induced abnormally elongated centrioles. This observation, coupled with the link between 
HPV-16 E7 and modulation of VHL containing E3 ubiquitin ligases activity, we decided to 
utilize a panel of proteasome inhibitors to examine the role of proteolysis in the control of 
centriole elongation and possibly cilia formation. We observed that cells exposed to either Z-
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L3VS or MG132 contain abnormally elongated daughter centrioles. Unexpectedly, we found that 
the elongated centrioles were daughter centrioles, and not elongated mother centrioles as occurs 
in the case of primary cilia. Abnormally elongated daughter centrioles were found to reach 
approximately four times the length of normal daughter centrioles. We demonstrate that the 
ability of Z-L3VS and MG132 to potently induce daughter centriole elongation correlates with 
sustained inhibition of the 26S proteasome. Other proteasome inhibitors were also able to induce 
abnormal centriole elongation, although to lesser extents. The fact that specific and potent 
proteasome inhibitors were less potent effectors of abnormal centriole elongation suggests a role 
of non-proteasomal activities, such as those against cellular proteases, in centriole length control. 
Combining our assay system of Z-L3VS-induced centriole elongation with an siRNA screen 
targeting 127 known centrosomal proteins [152], we were able to identify seven centrosomal 
proteins that attenuated daughter centriole elongation when knocked-down (FOP, CAP350, 
CPAP, hSAS-6, Cep170, ninein, and C-Nap1) and two centrosomal proteins that promoted this 
process when depleted (Cep97 and CP110). Our results reveal an unexpected complexity of 
daughter centriole length control and highlight the critical role of proteolysis in this process. 
4.2 MATERIALS AND METHODS 
Antibodies 
 Rabbit anti-Cep97 and CP110 were a kind gift from Brian Dynlacht (NYU Cancer 
Institute, New York, NY, USA) [145]. Mouse anti-Cep170 and mouse anti-ninein were a kind 
gift from Erich A. Nigg (Max Plank Institute of Biochemistry, Martinsried, Germany) [77]. 
Rabbit anti-CPAP was a kind gift from Tang K. Tang (Institute of Biomedical Sciences, Taipei, 
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Taiwan) [153]. Rabbit anti-CAP350 was obtained commercially from Novus Biologicals 
(Littleton, CO, USA). Rabbit anti-FGFR1OP was obtained commercially from Proteintech 
Group (Chicago, IL, USA). Mouse anti-C-Nap1 was obtained commercially from BD 
Transduction Laboratories (San Jose, CA, USA) and mouse anti-hSAS6 was obtained 
commercially from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
 
Cell culture and inhibitor treatment 
 The human U-2 OS osteosarcoma cells line was obtained from ATCC and 
maintained in Dulbecco's modified Eagle medium (DMEM; Cambrex, Walkersville, MD) 
supplemented with 10% fetal bovine serum (Mediatech, Herndon, VA), 50 units/ml penicillin, 
and 50 µg/ml streptomycin (Cambrex). U-2 OS cells were engineered to stably express a centrin-
GFP-encoding construct (kindly provided by Michel Bornens, Institut Curie, Paris, France). 
Proteasome inhibitors were used at the following concentrations that were associated with at 
least 50% viable cells after 72 h: Z-L3VS (used at a 1 µM concentration; Biomol, Plymouth 
Meeting, PA, USA), MG132 (used at a 1 µM concentration), MG262 (used at a 0.001 µM 
concentration), lactacystin (used at a 1 µM concentration; all Boston Biochem, Cambridge, MA, 
USA) and epoxomicin (used at a 0.01 µM concentration; Calbiochem, San Diego, CA, USA) 
were dissolved in DMSO. In all experiments, solvent controls were included using 0.1% DMSO. 
 
Small interfering RNA (siRNA) 
 Proteins to be tested in the siRNA screen were depleted using RNA duplexes 
(Qiagen, Valencia, CA, USA) targeting known centriolar associated proteins as described 
previously [152]. For the centriole elongation screen, U-2 OS/centrin-GFP cells were grown in 
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12-well tissue culture plates, on coverslips, with 0.5 mL DMEM free of antibiotics. Cells were 
transfected with 3 µL of 20 µM annealed RNA duplexes using Oligofectamine (Invitrogen, 
Carlsbad, CA, USA) transfection reagent. 24 h post transfection cells were treated with 1 µM of 
the proteasome inhibitor Z-L3VS and were analyzed 72 h post inhibitor addition. Primary and 
secondary siRNA screens were performed using target sequences shown in Suppl. Table 1. RNA 
duplexes that yielded a more than 20% increase or decrease of the proportion of cells with 
elongated centrioles normalized to Z-L3VS-treated, control siRNA-transfected cells in both 
rounds of screens were considered hits.   
For each immunofluorescence or immunoblotting experiment, U-2 OS/centrin-GFP cells 
were grown in 60 mm tissue culture dishes with 2 mL DMEM free of antibiotics. Cells were 
transfected with 12 µL of 20 µM annealed RNA duplexes using Oligofectamine transfection 
reagent and treated as above. Knock-down efficiency was monitored by western blot analysis or 
immunofluorescence microscopy. 
 
Immunoblotting 
For immunoblot analyses, cell lysates were prepared by scraping cells into lysis buffer 
(1% NP-40, 50 mM Tris-HCl pH 8.0, 100 mM sodium fluoride, 30 mM sodium pyrophosphate, 
2 mM sodium molybdate, 5 mM EDTA, 2 mM sodium orthovanadate in dH2O) containing 
protease inhibitors (10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 µM phenylmethylsulfonyl fluoride, 
2 µM vanadate). Lysates were incubated for 1 h with rotating at 4°C and then cleared by 
centrifugation for 30 min at 13,000 rpm at 4°C. Protein concentrations were determined by the 
Bradford assay (Biorad Laboratories, Hercules, CA, USA). 30 µg of protein was loaded on a 4-
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12% Bis-Tris or 3-8% Tris-Acetate gel (Invitrogen, Carlsbad, CA, USA) and blotted onto a 
nitrocellulose membrane.  
 
Immunofluorescence Microscopy 
For immunofluorescence microscopic analyses, cells grown on coverslips were fixed in 
4% paraformaldehyde/PBS for 15 min at room temperature, washed in PBS and permeabilized 
with 1% Triton-X-100 in PBS for 20 min. After blocking in 10% normal donkey serum (Jackson 
Immunoresearch, West Grove, PA, USA), cells were incubated with primary antibody overnight. 
The next morning, cells were warmed at 37°C for 2 h, washed in PBS and incubated with 
Rhodamine Red-conjugated secondary antibody for 2 h and mounted with DAPI. Cells were 
analyzed using an Olympus AX70 epifluorescence microscope equipped with a SpotRT digital 
camera.  
 
Electron Microscopy 
 For transmission electron microscopy, the samples were fixed for at least 1 hour in a 
2% glutaraldehyde solution buffered with PBS. After washing in three changes of PBS, the 
samples were placed in a 1% osmium tetroxide solution buffered with PBS for one hour, 
followed by a series of rinses with ethanol solutions of increasing concentration  (50%, 70%, 
95%, and 100%). The samples were then placed in a 1:1 mixture of Epon Araldite resin and 
propylene oxide, and held overnight in a desiccator. The following day, the Epon Araldite and 
propylene oxide mixture was removed and replaced with 100% Epon Araldite resin. The samples 
were infiltrated with the resin for an additional 8 h, placed in embedding molds and polymerized 
for 48 h at 60°C. Serial thin sections were cut using a Reichert-Jung Ultracut E ultramicrotome 
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and a DDK Diamond knife. Thin sections were picked up on copper grids and stained with 1% 
uranyl acetate and Reynold’s lead citrate. The sections were viewed on a Hitachi H-7100 TEM 
transmission electron microscope (Hitachi High Technologies America, Pleasanton, CA). Digital 
images were obtained using an AMT Advantage 10 CCD Camera System (Advanced 
Microscopy Techniques Corporation, Danvers, MA) and NIH Image software. 
 
Statistical Methods 
 Student’s t test for independent samples was used wherever applicable. 
4.3 RESULTS 
Inhibition of the Proteasome Induces Abnormal Elongation of Daughter Centrioles 
To examine the role of proteolysis in centriole biogenesis, we treated U-2 OS cells stably 
expressing green fluorescent protein (GFP)-tagged centrin (U-2 OS/centrin-GFP), with the 
proteasome inhibitor Z-L3VS [154]. Treatment of cells for 72 h with Z-L3VS was found to 
induce a significant elongation of centrioles (Figure 17A).  Elongated centrioles were typically 
arranged in a ‘flower’-like pattern around a large centrin-GFP dot an described before in Z-
L3VS-treated cells [80]. Occassionally elongated centrioles were found to have a bifurcated end 
(Figure 1A bottom left panel, arrow). This observation is similar to previous reports when 
abnormal centriole elongation was induced through prolonged overexpression of the protein 
CPAP [153, 155, 156]. Z-L3VS-induced abnormally elongated centrioles were stable and 
persisted in a significant proportion of cells for up to 72 h after removal of the drug (data not 
shown). 
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Figure 17. Inhibition of the proteasome stimulates aberrant centriole elongation. 
(A) Fluorescence microscopic analysis of U-2 OS cells stably expressing centrin-GFP after either treatment with 
0.1% DMSO (top left panel) or 1 µM Z-L3VS (remaining panels) for 72 h. Arrow indicates a bifurcated distal end of 
an elongated centriole. Arrowhead points to an example of an elongated centriole with segmentation of the centrin-
GFP signal. (B,C) Quantification of centriole length in U-2 OS/centrin GFP cells with abnormally elongated 
centrioles after treatment with 0.1% DMSO or 1 µM Z-L3VS for 72 h. Centriole length measurements were 
performed using ImageJ and expressed as arbitrary units (a.u.). (D) Quantification of the percentage of U-2 
OS/centrin-GFP cells containing elongated centrioles after treatment with Z-L3VS (1 µM), MG132 (1 µM), 
lactacystin (1 µM), MG262 (0.001 µM) and epoxomicin (0.01 µM) for 72 h. Cells treated with 0.1% DMSO for 72 
h were used as controls. All these inhibitor concentrations were associated with at least 50% cell viability. Each bar 
represents mean and standard error of at least two independent experiments with a minimum of 100 cells counted 
per experiment. Asterisks indicate statistically significant differences (p<0.0001; Student’s t test for independent 
samples). Legend is continued on following page.  
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(E) Immunoblot analysis of Gadd34 in U-2 OS/centrin-GFP cells after treatment with either 0.1% DMSO or Z-L3VS 
(1 µM), MG132 (1 µM), lactacystin (1 µM), MG262 (0.001 µM) and epoxomicin (0.01 µM) for 72 h. All these 
inhibitor concentrations were associated with at least 50% cell viability. Immunoblot for actin is shown to 
demonstrate protein loading. 
 
In order to assess the increase in centriole length induced by Z-L3VS in a semi-
quantitative manner, centriole length was measured using the ImageJ software 
(http://rsbweb.nih.gov/ij/) and expressed in arbitrary units (Figure 17B and 17C). In cells treated 
with Z-L3VS, the maximum length of individual centrioles (n=30) was considerably longer and 
varied widely compared to the shorter and more constant length of individual centrioles in 
DMSO-treated control cells (n=30), underscoring the intrinsic ability of centrioles to elongate to 
several times their normal length. 
We next tested a panel of different proteasome inhibitors for their ability to induce 
abnormal centriole elongation using a drug concentration that resulted in a cell viability of at 
least 50%. Quantification of cells with elongated centrioles revealed a significant 95.8-fold 
increase in populations treated with 1 µM Z-L3VS for 72 h (31.6%; p<0.0001) when compared to 
DMSO-treated controls (0.33%; Figure 17D). A significant increase of cells with elongated 
daughter centrioles, although to a lesser extent, was also detected in cells treated with the 
proteasome inhibitor MG132 (17.3%; p<0.0001) but not in cells treated with MG262, 
lactacystin, or epoximicin (Figure 17D).  
To confirm the role of proteolysis in centriole length control, we repeated these 
experiments with the proteasome inhibitors which did not initially induce centriole elongation at 
higher drug concentrations, albeit at the expense of cell viability. Cells treated with a ten-fold 
increase in concentration of MG262, a five-fold increase in concentration of epoxomicin, and a 
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ten-fold increase in concentration of lactacystin exhibited elongated centrioles in 2.0%, 3.7% and 
2.3% of cells, respectively (data not shown).  
Now that we demonstrated proteasome inhibition in general leads to abnormal centriole 
elongation, we next sought to determine why Z-L3VS and MG132 were much more potent 
inducers of abnormal daughter centriole elongation compared to the other proteasome inhibitors, 
in particular lactacystin. One explanation for this difference could be the efficacy and timing of 
proteasome inhibition achieved in U 2-OS/centrin-GFP cells. We addressed this by performing 
immunoblot analysis of Gadd34, a robust marker of 26S proteasome activity [157], following 
treatment with our panel of proteasome inhibitors at the original concentration leading to greater 
than 50% cell viability. Only treatment with Z-L3VS or MG132 promoted accumulation of 
Gadd34 at 72 h post-inhibitor treatment, the time point at which we assessed daughter centriole 
length (Figure 17E). This suggests that sustained inhibition of the 26S proteasome, among other 
factors (see Discussion), may play a role in Z-L3VS- or MG132-induced centriole elongation. 
To determine that the elongated centrin-positive structures observed in Z-L3VS-treated 
U-2 OS/centrin-GFP cells were in fact daughter centrioles, we examined Z-L3VS-treated cells by 
ultrathin serial section electron microscopy (EM). As shown in Figure 18A, the elongated 
structures observed were bona fide daughter centrioles as indicated by the lack of detectable 
appendages.  
While analyzing elongated daughter centrioles, we observed regions of the elongated 
daughter that contained less intense centrin staining (Figure 18A, arrowhead). This finding raised 
the question whether elongated daughters consist of centrin-containing segments or continuously 
elongated centriolar structures. To answer this question, we specifically analyzed these regions 
of abnormally elongated daughter centrioles. As shown in Figure 18B, we found microtubules  
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Figure 18. Inhibition of the proteasome stimulates elongation of daughter but not maternal centrioles. 
(A) Consecutive serial-section electron microscopic analysis of an abnormally elongated centriole after Z-
L3VS treatment of U-2 OS/centrin-GFP cells. Arrows point to an elongated daughter centriole. Scale bar indicates 
500 nm. (B) Consecutive serial-section electron microscopic analysis of a elongated daughter centriole after 72 h 
treatment of U-2 OS/centrin-GFP cells with Z-L3VS. Note the less electron dense area and the continuous 
microtubules that span this region (arrows). Scale bar indicates 100 nm. (C,D) Immunofluorescence microscopic 
analysis for Cep170 (C) and ninein (D) in U-2 OS/centrin-GFP cells after a 72 h treatment with the proteasome 
inhibitors Z-L3VS (1 µM) or 0.1% DMSO as control. Nuclei stained with DAPI. Scale bar indicates 10 µm. 
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spanning this electron dense region by ultrathin serial section EM, underscoring that elongated 
daughter centrioles consist of elongated centriolar microtubules and not discrete centrin-
containing segments.  
To further substantiate that these elongated structures represent elongated daughter 
centrioles, we performed immunofluorescence staining of Cep170 and ninein, two markers of 
mature maternal centrioles [77, 158]. Elongated centrioles were grouped around a central, 
maternal centriole and did not co-localize with either Cep170 or ninein, indicating that elongated 
centrin positive structures were indeed daughter centrioles (Figure 18C and 18D).  
Taken together, our results suggest that Z-L3VS and MG132 treatment leads to an 
abnormal elongation of daughter centriolar microtubules and that normal daughter centriole 
length is not a result of structural constraints but is controlled by proteolysis.  
 
Abnormal Elongation of Daughter Centrioles Involves Several Centrosomal Proteins 
In order to determine the underlying mechanisms of abnormal elongation of daughter 
centrioles, we performed an siRNA screen focusing on 127 proteins known to be associated with 
centrosomes [152] (data not shown). Twenty-four hours after siRNA-treatment of U-2 
OS/centrin-GFP cells, elongation of daughter centrioles was induced by treatment of cells with 
the proteasome inhibitor Z-L3VS for 72h. Protein depletion was assessed by immunoblot 
analysis or immunofluorescence microscopy (data not shown).  Of 127 proteins analyzed, 
depletion of nine centrosomal proteins reproducibly changed the percentage of cells containing 
elongated centrioles when normalized to Z-L3VS-treated control siRNA transfected cells, 
suggesting that the target proteins may be involved in regulating centriole elongation (Figure 
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Figure 19. An siRNA screen to identify centrosomal proteins involved in Z-L3VS-induced abnormal daughter 
centriole elongation. 
(A) U-2 OS-centrin/GFP cells were transfected for 24 h with control or siRNA duplexes targeting 127 known 
centrosomal proteins [152] followed by a 72 h exposure to the proteasome inhibitor Z-L3VS (1 µM) or 0.1% DMSO 
as control. Cells were analyzed by fluorescence microscopy to determine the proportion of cells that contained 
abnormally long daughter centrioles. The bar graph shows negative (black bars) and positive (grey bars) regulators 
of Z-L3VS-induced daughter centriole elongation. Legend is continued on following page. Each bar represents the 
 71 
proportion of cells containing elongated centrioles when normalized to Z-L3VS-treated cells transfected with control 
siRNA duplexes (set to 100%). Mean and standard error of at least two independent experiments with a minimum of 
100 cells counted per experiment is shown. (B,C) Immunofluorescence microscopic analysis for FOP (B) and 
CAP350 (C) in U-2 OS/centrin-GFP cells after a 72 h treatment with the proteasome inhibitors Z-L3VS, MG132, or 
lactacystin (all 1 µM). Treatment with 0.1% DMSO was used as control. Scale bar indicates 10 mm. (D) Co-
immunofluorescence microscopic analysis for FOP and CAP350 in U-2 OS/centrin-GFP cells after a 72 h treatment 
with the proteasome inhibitors Z-L3VS (1 µM) or 0.1% DMSO. Nuclei stained with DAPI.  
 
19A). Depletion of seven proteins, FOP, CAP350, CPAP, hSAS6, Cep170, ninein, and C-Nap1 
led to a decrease in the number of cells that contained elongated daughter centrioles, whereas 
depletion of two proteins, Cep97 and CP110, led to an increase in the number of cells that 
contained elongated daughter centrioles (Figure 19A). 
Depletion of two proteins implicated in microtubule anchoring and stability, FOP and 
CAP350 [159-161], significantly reduced the number of cells containing abnormally elongated 
daughter centrioles to 50.7% and 54.7%, respectively, of control siRNA transfected Z-L3VS-
treated cells. Furthermore, depletion of Cep97 and CP110, two proteins that were previously 
shown to suppress the formation of cilia [145], led to an increase in the number of cells that 
contained long centrioles to 162.7% and 153.3%, respectively of control siRNA transfected Z-
L3VS-treated cells. This is in line with previous results suggesting that CP110 plays a negative 
regulatory role in centriole elongation [153, 156].  
Depletion of hSAS-6, a structural protein which is required for daughter centriole 
synthesis [88], decreased the percentage of Z-L3VS-treated cells which contained long daughter 
centrioles to 76% of control siRNA Z-L3VS-treated cells (Figure 19A). In addition, depletion of 
CPAP, a protein that has previously been shown to play a role in centriole elongation [153, 155, 
156], also decreased the percentage of Z-L3VS-treated cells with long daughter centrioles to 
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73.2% of control siRNA Z-L3VS-treated cells (Figure 19A). Remarkably, depletion of proteins 
implicated either in maintaining centrosome cohesion or associated with maternal centriole 
appendages, C-Nap1 [162], ninein [158], and Cep170 [77], also caused a reduction in the number 
of cells containing long centrioles to 67.1%, 60.3%, and 72.6%, respectively, compared to 
control siRNA transfected Z-L3VS-treated cells (Figure 19A). 
Taken together, these results suggest that Z-L3VS-induced abnormal centriole elongation 
involves known positive and negative microtubule regulatory proteins as well as proteins 
involved in centrosome cohesion and microtubule anchoring.  
 
Z-L3VS Alters the Expression of Several Centriolar Proteins Involved in Length Control 
Next, we asked whether Z-L3VS or MG132-induced abnormal daughter centriole 
elongation was associated with alteration of the localization and/or abundance of the nine 
proteins we identified in our siRNA screen. First, we analyzed the localization of the two major 
microtubule stabilizing proteins identified in our screen, FOP and CAP350. Immunofluorescence 
microscopy of FOP in DMSO-treated control cells, showed FOP co-localizing with centrioles 
(Figure 19B, top panel), as previously noted [159, 161]. When cells were treated with Z-L3VS or 
MG132, staining for FOP was found to co-localize along elongated daughter centrioles (Figure 
19B, middle panels). However, when cells were treated with lactacystin, a proteasome inhibitor 
that is less potent to induce abnormal elongation of daughter centrioles, FOP localization was 
similar to that of DMSO-treated control cells (Figure 19B, bottom panels).  
Immunofluorescence microscopic analysis of CAP350 in DMSO-treated control cells 
showed CAP350 localization to both mother and daughter centrioles as previously reported [159, 
161] (Figure 19C, top panel). When CAP350 was analyzed after Z-L3VS or MG132-treatment, 
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we detected CAP350 co-localizing along elongated daughter centrioles, similar to the 
localization of FOP after treatment with these proteasome inhibitors (Figure 19C, middle panels). 
When cells were treated with lactacystin, CAP350 localization was comparable to that of 
DMSO-treated control cells (Figure 19C bottom panels). We confirmed the similar localization 
of FOP and CAP350 along elongated daughters by performing co-immunofluorescence 
microscopic analysis following Z-L3VS-treatment (Figure 19D).  
 To assess the accumulation of FOP and CAP350 protein, respectively, an immunoblot 
analysis of whole cell extracts from cells treated for 72 h with our panel of proteasome inhibitors 
was performed. Z-L3VS or MG132-treatment, which both induce abnormal elongation of 
daughter centrioles, resulted in the accumulation of both FOP and CAP350 to significantly 
higher levels than in DMSO-treated controls (Figure 20A). The proteasome inhibitors that were 
unable to induce abnormal daughter centriole elongation at concentrations associated with at 
least 50% cell viability, did not demonstrate an accumulation of either FOP or CAP350 
compared to DMSO-treated control cells (Figure 20A).  
 
Figure 20. Stabilization of FOP and CAP350 protein by both Z-L3VS and MG132 treatment.  
(A) Immunoblot analysis of FOP and CAP350 in U-2 OS/centrin-GFP cells after treatment with either 0.1% DMSO 
or proteasome inhibitors as indicated for 72 h. Immunoblot for actin is shown to demonstrate protein loading. Note 
accumulation of both CAP350 and FOP in Z-L3VS-treated cells. Legend is continued on the following page.     
 74 
(B) Quantification of the immunofluorescence intensity of FOP and CAP350 in U-2 OS/centrin GFP cells with 
abnormally elongated centrioles after treatment with 0.1% DMSO or 1 µM Z-L3VS for 72 h. Fluorescence intensity 
measurements were performed using ImageJ.   
 
To corroborate that accumulation of FOP and CAP350 was in fact occurring at the 
centrosome, we performed semi-quantitative analysis of centrosomal protein levels by 
immunofluorescence analysis using ImageJ software (Figure 20B). We found a 4.9-fold increase 
in FOP and a 5.3-fold increase in CAP350 protein levels in Z-L3VS-treated cells versus DMSO-
treated control cells. Furthermore, we analyzed individual centriole length upon transfection of 
siRNA duplexes targeting either FOP or CAP350, followed by Z-L3VS-treatment, as we had 
previously done in Figure 17B and 17C. We found that the maximum length of individual 
daughter centrioles was overall reduced compared to controls although the length of individual 
abnormally elongated daughter centrioles still varied widely (data not shown). Together, these 
results suggest that protein stabilization of both FOP and CAP350 through proteasome inhibition 
contributes to abnormal elongation of daughter centrioles.  
We next examined the localization of CPAP, a known microtubule-interacting protein 
that has recently been implicated in centriole length control, after treatment with proteasome 
inhibitors (Fig. 21). In DMSO-treated control cells, we saw CPAP localizing to both mother and 
daughter centrioles (Figure 21, top panel), as previously seen [153, 155, 156]. When we treated 
cells with Z-L3VS, CPAP co-localized with the centrin signal of elongated daughter centrioles 
(Figure 21, middle panel). However, when cells were treated with the proteasome inhibitor 
lactacystin at a concentration that did not lead to centriole elongation, CPAP localization was 
analogous to DMSO-treated control cells (Figure 21, bottom panel). This suggests that treatment 
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Figure 21. Alteration of CPAP localization following Z-L3VS treatment.  
Immunofluorescence microscopic analysis of CPAP in U-2 OS/centrin-GFP cells after treatment with 1 µM Z-L3VS 
for 72 h or 0.1% DMSO as control. Nuclei stained with DAPI. Scale bar indicates 10 µm.  
 
 with the proteasome inhibitor Z-L3VS leads to an accumulation of CPAP at elongated daughter 
centrioles.  
Although depletion of C-Nap1, hSAS-6, Cep170, and ninein decreased Z-L3VS mediated 
abnormal daughter centriole elongation in our siRNA screen, the localization of these proteins 
did not change in cells treated with any of our proteasome inhibitors (Figures 22). This suggests 
that, although treatment with Z-L3VS does not promote a significant change in phenotype of 
these proteins, the presence of C-Nap1, hSAS-6, Cep170, and ninein is necessary in order to 
promote Z-L3VS mediated abnormal daughter centriole elongation.  
We then determined the localization of CP110 and Cep97, two proteins whose depletion 
we found to increase the percentage of Z-L3VS treated cells that contained long daughter 
centrioles. Immunofluorescence microscopic analysis of CP110 and Cep97 in DMSO-treated 
control cells showed centriolar localization of both proteins (Figure 23A and 23B, top panels) in  
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Figure 22. Expression C-Nap1 and hSAS-6 following Z-L3VS treatment.  
(A,B) Immunofluorescence microscopic analysis for C-Nap1 (A) or hSAS-6 (B) in U-2 OS/centrin-GFP cells after a 
72 h treatment  with 1 µM the proteasome  inhibitor  Z-L3VS or with 1 µM lactacystin. Treatment  with 0.1% DMSO 
was used as control. Nuclei stained with DAPI. Scale bar indicates 10 µm. 
 
accordance with previously published findings [87, 145, 156, 163]. When cells were treated with 
Z-L3VS to induce abnormally elongated daughter centrioles, both CP110 and Cep97 localized to 
the tips of elongated daughters (Figure 23A and 23B, middle panel). Treatment of cells with 
lactacystin at concentrations that did not induce elongated daughter centrioles, resulted in a 
similar CP110 and Cep97 localization pattern as detected DMSO-treated controls (Figure 23A 
and 23B, bottom panels).  
Taken together, Z-L3VS-induced abnormal daughter cell elongation was associated with 
prominent changes in FOP, CAP350 and CPAP protein abundance and changes in localization at 
long daughter centrioles. Not all proteins identified in our siRNA screen followed this pattern  
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Figure 23. CP110 and Cep97 are retained at the tips of elongated daughter centrioles induced by Z-L3VS. 
(A,B) Immunofluorescence microscopic analysis of CP110 (A) and Cep97 (B) in U-2 OS/centrin-GFP cells after a 
72 h treatment with 1 µM of the proteasome inhibitors Z-L3VS or 1µM  lactacystin. Treatment with 0.1% DMSO
 was used as control. Note the localization of both CP110 and Cep97 to the distal ends of elongated daughter  
centrioles. Nuclei stained with DAPI. Scale bar indicates 10 µm.  
 
although most proteins showed an accumulation at centrioles by immunofluorescence 
microscopy (C-Nap1, hSAS-6, CEP170, ninein, Cep97; data not shown). Clearly, Z-L3VS-
induced abnormal centriole elongation was not due to displacement of CP110 and Cep97 from 
the distal tips of daughter centrioles (Fig. 23). However, the lack of increased CP110 protein 
levels in Z-L3VS- compared to DMSO-treated cells, as measured by immunofluorescence 
analysis, is in agreement with the role of CP110 as a negative regulator of centriole elongation 
[148-150]. Taken together, these results suggest that some proteins may play a direct role in 
aberrant microtubule elongation along the length of daughter centrioles whereas others may not 
function directly at daughter centrioles but are yet required for this process.  
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4.4 DISCUSSION 
The present report provides unexpected insights into the regulation of daughter centriole 
elongation and underscores the role of proteolysis in this process. We show that daughter 
centriole elongation is not controlled by structural constraints but is a highly regulated process 
that involves several more proteins than CPAP and CP110, which have previously been 
implicated in the regulation of centriole elongation. 
Since we only detected abnormally long daughter centrioles under our assay conditions, 
our findings suggest that mother and daughter centriole elongation are, to a certain degree, 
separable processes and can be distinguished by proteolytic inhibition.  The basis for this 
differential regulation is unknown but it is possible that cell cycle-dependent events play a role. 
Daughter centriole elongation predominantly occurs during S and G2 phases of the cell division 
cycle. Hence, the treatment with proteasome inhibitors Z-L3VS or MG132 may render cells 
competent for aberrant daughter centriole elongation through prolongation of a cell cycle stage 
that is permissive for this process. In line with this notion is our previous finding that Z-L3VS-
treated cells accumulate in G2 [80]. However, a cell cycle arrest per se is not sufficient to induce 
abnormal daughter centriole elongation since cells treated with epoxomycin contained a 
significant proportion of cells that were arrested in G2 phase of the cell division cycle (data not 
shown), but lacked the ability to produce abnormally long daughter centrioles (Fig. 17D). 
When we first tested different proteasome inhibitors for their ability to induce abnormal 
centriole elongation, we used a drug concentration that resulted in a cell viability of at least 50%. 
We repeated these experiments with higher concentrations of proteasome inhibitors and we 
found that, in principle, all proteasome inhibitors used were able to induce abnormally long 
centrioles, albeit associated with reduced cell viability and in an overall lower percentage of cells 
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that survived the treatment. Remarkably, abnormally elongated centrioles were virtually absent 
in DMSO-treated control cells. Collectively, these results confirm that proteasome inhibition 
leads to abnormal centriole elongation, however, to different extents.  
To determine why Z-L3VS and MG132 were much more potent inducers of abnormal 
daughter centriole elongation compared to the other proteasome inhibitors, in particular 
lactacystin, we tested their proteasome inhibitory activities by immunoblotting for Gadd34 [157]. 
We found that only treatment with Z-L3VS or MG132 promoted a sustained inhibition of the 26S 
proteasome at 72 h, which may explain why Z-L3VS and MG132, probably in conjunction with 
other characteristics (see below), are the most potent inducers of aberrant daughter centriole 
elongation. 
Although all proteasome inhibitors tested here have been shown to inhibit 26S 
proteasome activity, several of our inhibitors, most notably Z-L3VS and MG132, also have non-
proteasomal activities against cellular proteases. In contrast, other inhibitors such as lactacystin 
and epoxomicin are more potent and specific inhibitors of the 26S proteasome with less non-
proteasomal inhibitory activities. Nonetheless, these non-proteasomal activities may become 
more prominent at higher inhibitor concentrations and may play a role in the small amount of 
centriole elongation seen when inhibitors that did not score in our initial screen were used at 
higher concentrations. These results may furthermore suggest that non-proteasomal functions, 
specifically inhibition of cellular proteases, may play an important but currently 
underappreciated role in the regulation of centriole elongation. 
To determine what proteins were involved in abnormal daughter centriole elongation 
induced by Z-L3VS, we utilized an siRNA screen based on a previous study, in which 127 
centrosomally associated proteins were identified [152]. It is important to note that by using 
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targets identified in this previous study, we may be excluding centrosomal proteins not identified 
in this screen which could potentially play a role in centriole elongation control. 
We did not see a complete abolishment of abnormal centriole length in our siRNA screen 
and believe this is explained by the discrepancy between the rapid effects of proteasome 
inhibition on centriole biogenesis and the slower kinetics of maximum siRNA efficacy. Z-L3VS-
associated alterations of centriole biogenesis become visible already at 6 h after treatment and 
affect approximately 25% of cells after 24 h of treatment (our own unpublished results). It is 
generally accepted that siRNA-mediated knock-down of protein expression usually results in 
maximum protein depletion at approximately 48-72 h post-transfection. The residual extra long 
daughter centrioles that we observed are likely to have formed prior to complete knock-down of 
the targeted proteins.  
In addition, the abnormal centriole elongation phenotype reported here mostly arises in 
the context of centriole overduplication, specifically centriole multiplication, during which a 
single maternal centriole nucleates the concurrent formation of multiple daughter centrioles [80]. 
These supernumerary centrioles were very stable and persisted for prolonged time intervals [80]. 
In line with this notion, we found that Z-L3VS-induced abnormally elongated centrioles persisted 
in a significant proportion of cells for up to 72 h after removal of the drug. It is hence possible 
that abnormally elongated daughter centrioles that form in response to proteasome inhibition are 
particularly stable and less dynamic, a possibility that is currently under investigation. 
Nonetheless, results from this siRNA screen confirm and extend a number of previous 
studies. Recently, overexpression of CPAP was shown to induce the abnormal elongation of both 
mother and daughter centrioles [153, 155, 156]. CPAP protein level was shown to be cell cycle 
regulated through the action of the anaphase-promoting complex/cyclosome (APC/C) and the 
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26S proteasome [153]. Our screen confirms this role of CPAP in centriole elongation by showing 
that CPAP depletion reduces the number of cells which exhibit centriole elongation following Z-
L3VS-treatment.  
CPAP overexpression was found to synergize with depletion of another centriole 
component, CP110, in the formation of extra long centrioles [153, 155]. CP110 is a distal-end 
capping protein and knock-down of this protein alone can leads to centriole elongation and 
formation of primary cilia [145]. These results have suggested a simple model in which CPAP 
and CP110 act as positive and negative regulators, respectively, of centriole elongation. In line 
with this model, we found that depletion of either CP110, or a CP110 interacting partner Cep97, 
enhanced Z-L3VS-mediated daughter centriole elongation.  
However, our results significantly extend these previous studies by showing that a 
number of additional proteins besides CPAP and CP110 are involved in centriole length control. 
We found that FOP and CAP350 were also necessary for abnormal daughter centriole 
elongation, and significantly accumulate in Z-L3VS or MG132 treated cells. FOP and CAP350 
have been shown to interact and form a complex at the centrosome, with CAP350 necessary for 
FOP localization [159]. The FOP-CAP350 complex was shown to play a role in microtubule 
anchoring at the centrosome. However, both proteins also contain specific domains, in the case 
of FOP a LisH domain and of CAP350 a CAP-gly domain, which have been hypothesized to be 
involved in microtubule stability and dynamics [159, 164-166]; [160, 161]. Recently it was 
shown that neither FOP nor CAP350 depletion prevented initiation of procentriole synthesis, but 
that CAP350 was necessary for procentriole elongation to occur [161]. In line with this, we 
analyzed the individual length of daughter centrioles upon transfection of siRNA duplexes 
targeting either FOP or CAP350, followed by Z-L3VS-treatment, and found that the maximum 
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length of individual daughter centrioles was overall reduced compared to controls although the 
length of individual abnormally elongated daughter centrioles still varied widely (data not 
shown). The striking change in the expression pattern of both FOP and CAP350 shown here, 
along with the reduction of individual centriole length found in cells depleted of these two 
proteins, strengthens the hypothesis that these two proteins function to stabilize growing 
centriolar microtubules thereby promoting Z-L3VS and MG132-induced daughter centriole 
elongation.  
In addition, we show that hSAS-6, a structural centriolar component that is essential for 
daughter centriole synthesis [87, 88], is also necessary for abnormal centriolar elongation 
induced by Z-L3VS. Moreover, C-Nap1 a protein known to play a role in maintaining 
centrosome cohesion, as well as Cep170 and ninein, both proteins known to associate with 
maternal centriolar appendages, were also found to play a role in centriole length control. 
Depletion of Cep170 may interfere with microtubule-dependent trafficking to the centrosome 
[77], while depletion of ninein may result in the loss of microtubule anchoring at the centrosome 
[167]. Our results hence suggest that centrosome cohesion and microtubule-dependent processes 
are necessary for abnormal centriole elongation. Support for this notion comes from previous 
work suggesting that both centriolar and pericentriolar components are necessary for centriole 
assembly, possibly by concentrating the recruitment of components necessary for daughter 
centriole synthesis around the maternal centriole [74, 168]. We believe that the accumulation of 
hSAS-6, C-NAP1, CEP170 and ninein seen by immunofluorescence analysis, further supports 
the role of these proteins in Z-L3VS-induced daughter centriole elongation. Collectively, these 
results and results by others [88, 148] confirm and extend the notion that key regulators of Z-
L3VS-induced daughter centriole elongation are controlled by proteolysis. 
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In conclusion, we provide evidence that daughter centriole elongation is not limited by 
structural constrains but rather regulated by proteolysis. Our results suggest that maintaining the 
balance between positive and negative regulatory proteins is key for daughter centriole 
elongation control. We show that a number of additional proteins besides CPAP and CP110 are 
involved in this process including proteins known to play a role in centrosome cohesion and 
microtubule anchoring. This report illustrates the complex circuitry of centriolar proteins that 
regulate centriole biogenesis including daughter centriole length control and reveals a link 
between control of centriole elongation and the suppression of the cilia assembly pathway 
highlighting the critical role of proteolysis in this process. 
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5.0  GENERAL DISCUSSION 
Persistent infection with high-risk HPV is the major driving force in the development of 
cervical cancer. Aneuploidy is frequently found in pre-malignant high-risk HPV-associated 
lesions and is a critical factor for malignant progression. The high-risk HPV-16 E7 oncoprotein 
has been shown to promote centrosome abnormalities and numerical chromosomal instability 
thereby increasing the risk for aneuploidy and malignant progression, through mechanisms that 
are incompletely understood [169]. The purpose of this study was to answer several key 
questions: (1) How does proteolysis regulate centriole duplication control? (2) Through what 
mechanisms does HPV-16 E7 expression rapidly promote centriole multiplication? (3) Besides 
centriole duplication control, does proteolysis control other aspects of centriole biogenesis? This 
chapter will discuss our findings and highlight how HPV-16 E7 exploits the tight regulation of 
PLK4 protein levels by SCF ubiquitin ligase complexes to promote centriole multiplication. 
Finally, we will describe how proteolysis plays a major role in other aspects of centriole 
biogenesis and outline future studies to expand upon this role.  
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5.1 HOW DOES PROTEOLYSIS REGULATE CENTRIOLE DUPLICATION 
CONTROL? 
The discovery that inhibition of the proteasome strongly induced centriole multiplication 
suggested that ubiquitin-mediated proteolysis was important in maintaining normal centriole 
duplication control [80].  Here, we show that CUL1, the core component of SCF-ligase 
complexes, localizes to maternal centrioles which function as platforms for oncogene-induced 
centriole overduplication (Chapter 2; [134]). We show through siRNA-mediated depletion of 
CUL1 and transfection of a dominant-negative CUL1 construct that SCF-E3 ubiquitin ligase 
activity is necessary for restraining centriole multiplication. Further experiments revealed that 
overexpression of cyclin E/CDK2 mediates the aberrant recruitment of PLK4 to maternal 
centrioles. However, endogenous levels of PLK4 were not sufficient to induce centriole 
multiplication and a concomitant increase in PLK4 protein levels was necessary for this event to 
occur. Subsequently, PLK4 protein was found to be degraded by the proteasome and regulated in 
a PLK4 kinase activity-dependent manner by cyclin E/CDK2. This regulation of PLK4 by the 
important cell cycle mediators CDK2 and cyclin E may represent a cellular failsafe mechanism 
to limit normal centriole biogenesis to once and only once per cell division cycle (Chapter 2; 
[134]). We furthermore show that CUL1 contributes to the control of PLK4 protein levels and 
active SCF complexes are necessary for this regulation. This was evidenced by accumulation of 
excess endogenous PLK4 at maternal centrioles following ectopic expression of a dominant-
negative CUL1 (DN-CUL1) construct. In addition, ectopic expression of DN-CUL1 along with 
CDK2 and cyclin E abrogated the activity-dependent degradation of PLK4. Overexpression of 
CAND1, an inhibitor of SCF-ligase complexes, led to an enhancement in centriole multiplication 
over that induced by PLK4 overexpression alone. CAND1 overexpression was shown to stabilize 
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PLK4 protein levels (Chapter 2; [134]). Collectively, these results underscore the importance of 
SCF E3 ligase mediated proteolysis in restraining centriole biogenesis and maintaining normal 
centriole duplication control.  
It is important to note that ubiquitin-mediated proteolysis is not the only mechanism 
which controls PLK4 protein stability. The PLK4 protein coding sequence has been reported to 
contain a PEST domain implicated in the mediation of rapid protein degradation by intracellular 
proteases [170, 171]. Further experiments to determine if PEST-domain mediated PLK4 
degradation may play a role in controlling centriole duplication processes are required and are 
currently underway. 
 
How is PLK4 recognized for SCF-mediated proteolytic degradation? 
There are over 70 known human F-box proteins which control the substrate specificity of 
SCF-ligase complexes [128]. Most substrates require phosphorylation to interact with the F-box 
protein of an SCF complex. Phosphorylation allows for substrate discrimination by SCF-ligases 
due to the specific recognition of phosphorylated motifs (phosphodegrons) [172]. A 
phosphodegron is one or a series of phosphorylated residues on a substrate that directly interacts 
with a protein–protein interaction domain in an E3 ubiquitin-ligase, such as an F-box containing 
protein [173].  
Several studies performed in Drosophila melanogaster cells report Slimb as the F-box 
protein which targets PLK4 for degradation [98, 99]. Drosophila PLK4 was found to contain a 
specific phosphodegron motif, conserved in higher eukaryotes, including humans, which 
mediates an interaction with Slimb. When either the phosphodegron of D. melanogaster PLK4 
was mutated or Slimb was knocked-down by siRNA, PLK4 protein levels accumulated [98]. 
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Despite this, efforts to define a role for β-TrCP, the mammalian homolog of Slimb, in human 
cells had inconsistent results [174, 175].  
We have performed an siRNA-mediated screen in U-2 OS/centrin-GFP cells of all known 
human F-box proteins to assay for induction of centriole multiplication. The goal of this screen 
was to determine the F-box responsible for PLK4 recognition and subsequent degradation in 
human cells. Although we failed to observe centriole multiplication following knock-down of β-
TrCP, we did identify 12 other F-box proteins whose knock-down led to a significant increase in 
centriole multiplication over control siRNA treated cells. This suggests that PLK4 protein 
stability and recognition may be regulated by several different F-box proteins. Nonetheless, β-
TrCP1-/- mice do exhibit lengthened mitosis, centrosome overduplication, multipolar metaphase 
spindles and misaligned chromosomes [132]. However, β-TrCP recognizes several key cell cycle 
regulators, such as claspin, CDC25a and Wee1, suggesting that this mouse model may present 
confounding cell cycle dysregulation. The coincidence of aberrant centrosome numbers and 
nuclear abnormalities observed in this model may be due to centrosome accumulation and not 
genuine centrosome overduplication  
PLK4 is known to autophosphorylate and our present study, as well as several previous 
reports, suggests that autophosphorylation may influence the proteolytic degradation of PLK4 
(Chapter 2; [98, 99, 134]). This autophosphorylation may induce a conformational change or 
prime a phosphodegron to promote PLK4 degradation. In line with this hypothesis, PLK4 was 
recently found to contain a 24 amino-acid (a.a.) autophosphorylation domain containing 13 
phospho-residues [174, 175]. Part of the putative PEST domain, previously proposed to 
destabilize PLK4, and the β-TrCP phosphodegron motif are contained within this region. 
Deletion of either the 24 a.a. autophosphorylation region or the kinase domain, dramatically 
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stabilized PLK4 protein levels [174]. When both phosphorylation sites of the β-TrCP 
phosphodegron motif were mutated to alanine, β-TrCP was unable to bind the mutated PLK4 
construct. Intriguingly, this mutated protein was still able to be ubiquitinated and was only 
slightly more stable than wild-type PLK4 [174]. Thus, β-TrCP may play only a minor role in the 
ubiquitin-mediated degradation of PLK4 in human cells underscoring the potential role of either 
multiple F-box proteins, alternative E3 ubiquitin ligases or cellular proteases in the regulation of 
PLK4 stability. 
Complex proteolytic regulation is seen for key cell cycle regulators such as cyclin E, 
which is recognized for degradation by more than one F-box protein [176, 177]. Our results 
suggest that CUL1 controls multiple aspects of PLK4 regulation including both the baseline 
protein level and its activity-dependent degradation (Chapter 2; [134]). Recognition of active and 
inactive pools of PLK4 is likely to be mediated by multiple F-box proteins and/or multiple 
CRLs.  
Only a handful of downstream PLK4 targets have been identified in human cells 
including the transcription factor Hand1 and the phosphatase CDC25C. However, the role of 
these proteins in centriole biogenesis remains to be determined. Discovering downstream PLK4 
targets relevant to centriole biogenesis and determining how these proteins are affected by both 
overexpression and depletion of PLK4 may also help in determining how PLK4 is regulated. 
Elucidating the exact role of CRL complexes in mediating centriole duplication control 
will provide invaluable information about the regulatory control of centrosomal proteins and 
perhaps identify new proteins which may be therapeutic targets for the prevention of genomic 
instability and malignant progression in both non-HPV and high-risk HPV associated lesions.  
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5.2 MECHANISMS OF RAPID INDUCTION OF CENTRIOLE MULTIPLICATION 
BY HPV-16 E7 
Elucidation of some of the molecular components necessary for centriole multiplication 
provided new insights into the mechanism of HPV-16 E7 induction of this pathway [134]. Here, 
we show that stable HPV-16 E7 expression promotes excess recruitment of PLK4 to maternal 
centrioles in the form of aberrant PLK4 dots (Chapter 3). Previous results have shown that the 
aberrant recruitment of endogenous PLK4 was not sufficient to induce centriole multiplication 
and that a concomitant increase in PLK4 protein level was necessary (Chapter 2; [134]). We 
found that HPV-16 E7 expression mediates a small but reproducible increase of PLK4 mRNA 
levels compared to control cells (Chapter 3). This increase was found to be both pRB- and, at 
least in part, HDAC-dependent. Finally, we show that upregulation of PLK4 mRNA 
corresponded with the ability of HPV-16 E7 to induce centriole multiplication. Together, these 
results demonstrate that enhancement of PLK4 mRNA abundance, possibly in an E2F-dependent 
manner, and aberrant recruitment of excess PLK4 to maternal centrioles may trigger HPV-16 E7-
induced centriole multiplication. 
In vitro studies have demonstrated that PLK4 overexpression in tissue culture results in 
an increase in supernumerary centrosomes and when PLK4 is depleted via RNA interference, 
centriole numbers are reduced with progressive loss of centrioles and the subsequent 
development of mono-polar spindles [76]. These observations suggest that a strict control of 
PLK4 transcript and protein levels is necessary to maintain cell viability. Although the threshold 
level of PLK4 protein which induces centriole multiplication is not known, our own experiments 
have shown that very small changes in PLK4 protein level induces a small but significant 
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percentage of cells to exhibit centriole multiplication which may ultimately promote a tolerable 
level chromosomal instability (Chapter 2; [134]).  
CUL1 depletion by RNA interference phenocopies HPV-16 E7-induced centriole 
multiplication (Chapter 2; [134]). This suggests that HPV-16 E7 expression may not only 
upregulate PLK4 mRNA but may also interfere with CUL1-mediated proteolytic control at 
maternal centrioles in order to promote PLK4 protein accumulation. We were unable to detect a 
change in CUL1 activity as determined by either decreased neddylation or increased CAND1 
association by western blot in HPV-16 E7 expressing cells (data not shown), despite the fact that 
the CAND1 promoter contains E2F-responsive elements. This does not rule out that small 
differences of CAND1 protein level at the centrosome may occur that were below detectable 
levels in our assays. Further experiments are necessary to determine if the HPV-16 E7 
oncoprotein may either enhance CSN activity or increase CAND1 abundance at the centrosome, 
promoting CUL1 deneddylation and dampening SCF-ligase activity at maternal centrioles. 
One report suggested that HPV-16 E7 requires the protease calpain to degrade pRB 
[178]. This finding raises the possibility that HPV-16 E7 may interfere with host cellular 
proteases, also implicated in PLK4 protein stability, which may promote increased PLK4 protein 
at maternal centrioles.  
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5.3 DOES PROTEOLYSIS CONTROL OTHER ASPECTS OF CENTRIOLE 
BIOGENESIS? 
The observation that a small but reproducible percentage of HPV-16 E7 expressing cells 
exhibited elongated centrioles led us to further examine the mechanisms that control centriole 
elongation.   
Primary cilia form in quiescent cells following migration of the maternal centriole to the 
cell surface to form the basal body. The basal body then elongates to form primary cilia which  
act as sensory organelles to control several important cellular signaling pathways [147]. The 
conversion from a maternal centriole to a basal body is not well understood however, previous 
reports had suggested that knock-down of Cep97 or CP110 promoted the aberrant formation of 
primary cilia in cycling cells [145]. Furthermore, overexpression of CP110 led to the suppression 
of cilia formation in quiescent 3T3 cells [145].  
We found that prolonged treatment of U-2 OS/centrin-GFP cells with the protesasome 
inhibitor Z-L3VS induced abnormally elongated daughter centrioles an important difference in 
comparison to basal body formation where elongation originates from the maternal centriole. To 
exploit this observation, we combined our assay system of Z-L3VS-induced abnormal centriole 
elongation with an siRNA screen targeting 127 known centrosomal proteins [152] to identify 
proteins involved in centriole length control (Chapter 4). We were able to discover seven 
centrosomal proteins that attenuated abnormal centriole elongation when knocked-down (FOP, 
CAP350, CPAP, hSAS-6, Cep170, ninein, and C-Nap1) and two centrosomal proteins that 
promoted this process when depleted (Cep97 and CP110). Subsequently we discovered that 
treatment with either Z-L3VS or MG132 led to the selective elongation of daughter centrioles.  
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Several other groups have recently found that overexpression of the centriolar structural 
protein CPAP resulted in the formation of extra long centrioles [148-150]. These were shown to 
represent elongated centrioles, and not cilia, based on transmission electron microscopy 
comparison between these structures and bona fide cilia [149, 150]. Subsequently, it was shown 
that induction of CPAP overexpression led to the elongation of both mother and daughter 
centrioles [148]. Further, CPAP protein level demonstrated cell-cycle regulation with low protein 
level in G1 which increased as cells entered mitosis. Intriguingly, CPAP protein level was found 
to be controlled by ubiquitin-mediated degradation through interaction with the APC/C during 
late mitosis [148].  
Our results confirm and extend these findings describing the accumulation of several 
other structural proteins along with CPAP following Z-L3VS or MG132 treatment. Furthermore, 
our findings demonstrate that Z-L3VS-mediated abnormal centriole elongation may be a more 
complicated process than was suggested by previous studies. CPAP contains an α/β tubulin-
binding domain and overexpression by itself may promote the assembly of centriolar 
microtubules to promote abnormal centriole elongation [148]. In contrast, abnormal centriole 
elongation in cells treated with either Z-L3VS or MG132 may require a number of structural 
proteins besides CPAP to accumulate and hence requires a functional centrosome for the 
concentration of these components. 
HPV-16 E7 expressing cells accumulate PLK1 whose destruction by the APC/CCdh1-
complex plays a role in mitotic exit in human cells [179, 180]. This overexpression of PLK1 may 
promote a prolonged mitosis and the aberrant accumulation of centrosomal structural proteins, 
such as CPAP, which are degraded upon mitotic exit and are also substrates of the APC/CCdh1 
[148]. This aberrant increase in centrosomal structural proteins may promote a small percentage 
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of cells to exhibit elongated centrioles. Moreover, HPV-16 E7 physically interacts with γ-tubulin, 
an important regulator of centriole biogenesis [74, 82]. This interaction may alter γ-tubulin 
dynamics facilitating the recruitment of components necessary for centriole elongation around 
the maternal centriole therefore promoting the abnormal elongation of centrioles we observed.   
Collectively, our results revealed an unexpected level of complexity in the maintenance 
of centriole length control and highlighted the critical role of proteolysis in this process. 
5.4 A COMPREHENSIVE MODEL OF HPV-16 E7 MEDIATED DISRUPTION OF 
CENTRIOLE BIOGENESIS  
Based on the results presented in this report, we suggest a model of how HPV-16 E7 
leads to a rapid induction of centriole multiplication as a cause of genomic instability and 
ultimately malignant progression (Figure 24).  
HPV-16 E7 promotes the formation of an S-phase like milieu through binding and 
degradation of pRB family members, interaction with histone deacetylases (HDACs) and 
inactivation of the CDK inhibitors p21Cip1 and p27Kip1. This, in turn, upregulates E2F-mediated 
gene transcription, including cyclin E, and prevents the inactivation of CDKs. Aberrant 
CDK2/cyclin E activity promotes the aberrant recruitment of PLK4 to the wall of maternal 
centrioles (Chapter 2; [134]). Endogenous levels of PLK4 are kept to low levels in order to 
prevent centriole overduplication from occurring through the action of CUL1-based E3 ligase 
complexes at maternal centrioles.  
However, deregulation of E2F-target expression by HPV-16 E7 may also lead to a 
modest increase in PLK4 mRNA levels (Chapter 3). This increase in PLK4 mRNA, along with  
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Figure 24. HPV-16 E7 and the complexity of centriole duplication control 
HPV-16 E7 induces the formation of an S-phase like milieu through binding and degradation of pRB-family 
members, interaction with histone deacetylases (HDACs) and inactivation of the CDK inhibitors p21Cip1 and p27Kip1, 
ultimately promoting the deregulation of E2F-mediated gene transcription and the aberrant activation of cyclin 
E/CDK2 complexes. This promotes centriole multiplication through the aberrant recruitment of PLK4 protein to 
maternal centrioles in the form of multiple PLK4 dots. A modest increase in PLK4 mRNA, coupled with local 
interference of SCF-mediated proteolytic control at maternal centrioles, may promote HPV-16 E7 mediated PLK4 
protein accumulation. Alternative CRL complexes formed by the remaining six known human cullin-subunits may 
also play a role in centriole duplication control. A second proteolytic system restrains abnormal daughter centriole 
elongation and seven centrosomal proteins were found to be necessary for promotion of Z-L3VS mediated daughter 
centriole elongation. These results highlight the importance of the proteolytic control of centriole biogenesis and 
suggest a mechanism by which the HPV-16 E7 oncoprotein promotes centrioles multiplication and ultimately viral 
carcinogenesis.   
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de-regulated cyclin E/CDK2, may lead to an accumulation of PLK4 protein at maternal 
centrioles in the form of aberrant PLK4 dots and ultimately centriole multiplication. An 
alternate, however not mutually exclusive mechanism, may be the local interfere of CUL1-based 
E3 ligase control of PLK4 at maternal centrioles by HPV-16 E7 or deregulation of cellular 
proteases. Disruption of CUL1-based E3 ligase control may occur through the enhancement of 
CAND1 protein level at the centrosome which may promote PLK4 protein accumulation above a 
certain threshold level necessary for centriole multiplication. CRL complexes formed by the 
remaining six known human cullin-subunits may also play a role in centriole duplication control.  
HPV-16 E7 was also observed to induce a small but reproducible percentage of cells to 
exhibit elongated centrioles and we discovered that centriole elongation control also involves 
proteolysis. These results provide a framework for further studies to explore the regulatory 
network which controls this process. The biological significance of abnormally elongated 
centrioles in HPV-16 E7 expressing cells remains to be determined. 
Collectively, results presented here highlight the complexity of centriole biogenesis in 
human cells and underscore the intrinsic ability of HPV-16 E7 to deregulate this process. 
5.5 FUTURE DIRECTIONS  
Work described in this thesis outlines the role of proteolysis in restraining centriole 
duplication and how the HPV-16 E7 oncoprotein manipulates this system to induce centriole 
multiplication. Additionally, we define another role for proteolysis in centriole biogenesis, 
specifically in the regulation of daughter centriole elongation. Our future work will focus on the 
following questions: (1) What is the exact role of pRB and HDACs in HPV-16 E7 mediated 
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upregulation of PLK4 mRNA? (2) Does HPV-16 E7 modulate cellular proteases to induce 
centriole duplication defects? (3) What is the F-box(es) responsible for PLK4 recognition and 
subsequent degradation? (4) Can CDK2 and PLK4 small molecule inhibitors be used as 
therapeutics to prevent the progression of both high-risk HPV and non-HPV associated pre-
invasive lesions? 
Centrosome abnormalities are found in several human malignancies and have been 
proposed to be the driving force in promoting chromosomal instability and carcinogenic 
progression [65, 181]. Based on the findings here, and those reported by others, we believe that 
CDK2 and PLK4 small molecule inhibitors could be utilized to prevent the progression of pre-
invasive high-risk HPV-associated and non-HPV associated lesions [182]. Future studies in our 
lab will focus on preliminary experiments to determine the efficacy of the combination of these 
therapies on the prevention of centrosome-mediated genomic instability.    
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